Chemistry:Antidepressant

From HandWiki
Short description: Class of medication used to treat depression and other conditions
Antidepressant
Drug class
Class identifiers
UseDepressive disorders, anxiety disorders, chronic pain, and addiction
ATC codeN06A
Mechanism of actionVaries
Chemical classVaries
Clinical data
Drugs.comDrug Classes
Consumer ReportsBest Buy Drugs
WebMDMedicineNet  RxList
External links
MeSHD000928
The skeletal structure of the SNRI venlafaxine, a typical example of an antidepressant.

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.[1]

Common side effects of antidepressants include dry mouth, weight gain, dizziness, headaches, akathisia,[2] sexual dysfunction,[3][4][5][6][7] and emotional blunting.[8][9][10] There is an increased risk of suicidal thinking and behavior when taken by children, adolescents, and young adults.[11] Discontinuation syndrome, which resembles recurrent depression in the case of the SSRI class, may occur after stopping the intake of any antidepressant, having effects which may be permanent and irreversible.[12][13]

Research regarding the effectiveness of antidepressants for depression in adults is controversial and has found both benefits[14] and drawbacks.[15] Meanwhile, evidence of benefit in children and adolescents is unclear,[16][17] even though antidepressant use has considerably increased in children and adolescents in the 2000s.[18] While a 2018 study found that the 21 most commonly prescribed antidepressant medications were slightly more effective than placebos for the short-term (acute) treatments of adults with major depressive disorder,[19][20] other research has found that the placebo effect may account for most or all of the drugs' observed efficacy.[21][22]

Research on the effectiveness of antidepressants is generally done on people who have severe symptoms,[23] a population that exhibits much weaker placebo responses,[24] meaning that the results may not be extrapolated to the general population that has not (or has not yet) been diagnosed with anxiety or depression.[20]


Medical uses

Antidepressants are prescribed to treat major depressive disorder (MDD), anxiety disorders, chronic pain, and some addictions. Antidepressants are often used in combination with one another.[1]

Despite its longstanding prominence in pharmaceutical advertising, the idea that low serotonin levels cause depression is not supported by scientific evidence.[25][26][27] Proponents of the monoamine hypothesis of depression recommend choosing an antidepressant which impacts the most prominent symptoms. Under this practice, for example, a person with MDD who is also anxious or irritable would be treated with selective serotonin reuptake inhibitors (SSRIs) or norepinephrine reuptake inhibitors, while a person suffering from loss of energy and enjoyment of life would take a norepinephrine–dopamine reuptake inhibitor.[28]

Major depressive disorder

The UK National Institute for Health and Care Excellence (NICE)'s 2022 guidelines indicate that antidepressants should not be routinely used for the initial treatment of mild depression, "unless that is the person's preference".[29] The guidelines recommended that antidepressant treatment be considered:

  • For people with a history of moderate or severe depression.
  • For people with mild depression that has been present for an extended period.
  • As a first-line treatment for moderate to severe depression.
  • As a second-line treatment for mild depression that persists after other interventions.

The guidelines further note that in most cases, antidepressants should be used in combination with psychosocial interventions and should be continued for at least six months to reduce the risk of relapse and that SSRIs are typically better tolerated than other antidepressants.[29]

American Psychiatric Association (APA) treatment guidelines recommend that initial treatment be individually tailored based on factors including the severity of symptoms, co-existing disorders, prior treatment experience, and the person's preference. Options may include antidepressants, psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or light therapy. The APA recommends antidepressant medication as an initial treatment choice in people with mild, moderate, or severe major depression, and that should be given to all people with severe depression unless ECT is planned.[30]

Reviews of antidepressants generally find that they benefit adults with depression.[20][14] On the other hand, some contend that most studies on antidepressant medication are confounded by several biases: the lack of an active placebo, which means that many people in the placebo arm of a double-blind study may deduce that they are not getting any true treatment, thus destroying double-blindness; a short follow up after termination of treatment; non-systematic recording of adverse effects; very strict exclusion criteria in samples of patients; studies being paid for by the industry; selective publication of results. This means that the small beneficial effects that are found may not be statistically significant.[31][32][33][34][15]

Among the 21 most commonly prescribed antidepressants, the most effective and well-tolerated are escitalopram, paroxetine, sertraline, agomelatine, and mirtazapine.[19][20] For children and adolescents with moderate to severe depressive disorder, some evidence suggests fluoxetine (either with or without cognitive behavioral therapy) is the best treatment, but more research is needed to be certain.[35][36][37][38] Sertraline, escitalopram, and duloxetine may also help reduce symptoms.[38]

A 2023 systematic review and meta-analysis of randomized controlled trials of antidepressants for major depressive disorder found that the medications provided only small or doubtful benefits in terms of quality of life.[39] Likewise, a 2022 systematic review and meta-analysis of randomized controlled trials of antidepressants for major depressive disorder in children and adolescents found small improvements in quality of life.[40] Quality of life as an outcome measure is often selectively reported in trials of antidepressants.[41]

Anxiety disorders

For children and adolescents, fluvoxamine is effective in treating a range of anxiety disorders.[42][37][43] Fluoxetine, sertraline, and paroxetine can also help with managing various forms of anxiety in children and adolescents.[42][37][43]

Meta-analyses of published and unpublished trials have found that antidepressants have a placebo-subtracted effect size (standardized mean difference or SMD) in the treatment of anxiety disorders of around 0.3, which equates to a small improvement and is roughly the same magnitude of benefit as their effectiveness in the treatment of depression.[44] The effect size (SMD) for improvement with placebo in trials of antidepressants for anxiety disorders is approximately 1.0, which is a large improvement in terms of effect size definitions.[45] In relation to this, most of the benefit of antidepressants for anxiety disorders is attributable to placebo responses rather than to the effects of the antidepressants themselves.[44][45]

Generalized anxiety disorder

Antidepressants are recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of generalized anxiety disorder (GAD) that has failed to respond to conservative measures such as education and self-help activities. GAD is a common disorder in which the central feature is excessively worrying about numerous events. Key symptoms include excessive anxiety about events and issues going on around them and difficulty controlling worrisome thoughts that persists for at least 6 months.

Antidepressants provide a modest to moderate reduction in anxiety in GAD.[46] The efficacy of different antidepressants is similar.[46]

Social anxiety disorder

Some antidepressants are used as a treatment for social anxiety disorder, but their efficacy is not entirely convincing, as only a small proportion of antidepressants showed some effectiveness for this condition. Paroxetine was the first drug to be FDA-approved for this disorder. Its efficacy is considered beneficial, although not everyone responds favorably to the drug. Sertraline and fluvoxamine extended-release were later approved for it as well, while escitalopram is used off-label with acceptable efficiency. However, there is not enough evidence to support Citalopram for treating social anxiety disorder, and fluoxetine was no better than a placebo in clinical trials. SSRIs are used as a first-line treatment for social anxiety, but they do not work for everyone. One alternative would be venlafaxine, an SNRI, which has shown benefits for social phobia in five clinical trials against a placebo, while the other SNRIs are not considered particularly useful for this disorder as many of them did not undergo testing for it. (As of 2008), it is unclear if duloxetine and desvenlafaxine can provide benefits for people with social anxiety. However, another class of antidepressants called MAOIs are considered effective for social anxiety, but they come with many unwanted side effects and are rarely used. Phenelzine was shown to be a good treatment option, but its use is limited by dietary restrictions. Moclobemide is a RIMA and showed mixed results, but still received approval in some European countries for social anxiety disorder. TCA antidepressants, such as clomipramine and imipramine, are not considered effective for this anxiety disorder in particular. This leaves out SSRIs such as paroxetine, sertraline, and fluvoxamine CR as acceptable and tolerated treatment options for this disorder.[47][48]

Obsessive–compulsive disorder

SSRIs are a second-line treatment for adult obsessive–compulsive disorder (OCD) with mild functional impairment, and a first-line treatment for those with moderate or severe impairment.[49][50][51][52]

In children, SSRIs are considered as a second-line therapy in those with moderate-to-severe impairment, with close monitoring for psychiatric adverse effects.[53] Sertraline and fluoxetine are effective in treating OCD for children and adolescents.[42][37][43]

Clomipramine, a TCA drug, is considered effective and useful for OCD. However, it is used as a second-line treatment because it is less well-tolerated than SSRIs. Despite this, it has not shown superiority to fluvoxamine in trials. All SSRIs can be used effectively for OCD. SNRI use may also be attempted, though no SNRIs have been approved for the treatment of OCD. Despite these treatment options, many patients remain symptomatic after initiating the medication, and less than half achieve remission.[54]

Placebo responses are a large component of the benefit of antidepressants in the treatment of depression and anxiety.[44][45] However, placebo responses with antidepressants are lower in magnitude in the treatment of OCD compared to depression and anxiety.[45][55] A 2019 meta-analysis found placebo improvement effect sizes (SMD) of about 1.2 for depression, 1.0 for anxiety disorders, and 0.6 for OCD with antidepressants.[45]

Post–traumatic stress disorder

Antidepressants are one of the treatment options for PTSD. However, their efficacy is not well established. Paroxetine and sertraline have been FDA approved for the treatment of PTSD. Paroxetine has slightly higher response and remission rates than sertraline for this condition. However, neither drug is considered very helpful for a broad patient demographic. Fluoxetine and venlafaxine are used off-label. Fluoxetine has produced unsatisfactory mixed results. Venlafaxine showed response rates of 78%, which is significantly higher than what paroxetine and sertraline achieved. However, it did not address as many symptoms of PTSD as paroxetine and sertraline, in part due to the fact that venlafaxine is an SNRI. This class of drugs inhibits the reuptake of norepinephrine, which may cause anxiety in some patients. Fluvoxamine, escitalopram, and citalopram were not well-tested for this disorder. MAOIs, while some of them may be helpful, are not used much because of their unwanted side effects. This leaves paroxetine and sertraline as acceptable treatment options for some people, although more effective antidepressants are needed.[56]

Panic disorder

Panic disorder is treated relatively well with medications compared to other disorders. Several classes of antidepressants have shown efficacy for this disorder, with SSRIs and SNRIs used first-line. Paroxetine, sertraline, and fluoxetine are FDA-approved for panic disorder, while fluvoxamine, escitalopram, and citalopram are also considered effective for them. SNRI venlafaxine is also approved for this condition. Unlike social anxiety and PTSD, some TCAs antidepressants, like clomipramine and imipramine, have shown efficacy for panic disorder. Moreover, the MAOI phenelzine is also considered useful. Panic disorder has many drugs for its treatment. However, the starting dose must be lower than the one used for major depressive disorder because people have reported an increase in anxiety as a result of starting the medication. In conclusion, while panic disorder's treatment options seem acceptable and useful for this condition, many people are still symptomatic after treatment with residual symptoms.[57][58][59]

Eating disorders

Antidepressants are recommended as an alternative or additional first step to self-help programs in the treatment of bulimia nervosa.[60] SSRIs (fluoxetine in particular) are preferred over other antidepressants due to their acceptability, tolerability, and superior reduction of symptoms in short-term trials. Long-term efficacy remains poorly characterized. Bupropion is not recommended for the treatment of eating disorders, due to an increased risk of seizure.[61]

Similar recommendations apply to binge eating disorder.[60] SSRIs provide short-term reductions in binge eating behavior, but have not been associated with significant weight loss.[62]

Clinical trials have generated mostly negative results for the use of SSRIs in the treatment of anorexia nervosa.[63] Treatment guidelines from the National Institute of Health and Care Excellence (NICE)[60] recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association (APA) note that SSRIs confer no advantage regarding weight gain, but may be used for the treatment of co-existing depressive, anxiety, or obsessive–compulsive disorders.[62]

Pain

Fibromyalgia

A 2012 meta-analysis concluded that antidepressant treatment favorably affects pain, health-related quality of life, depression, and sleep in fibromyalgia syndrome. Tricyclics appear to be the most effective class, with moderate effects on pain and sleep, and small effects on fatigue and health-related quality of life. The fraction of people experiencing a 30% pain reduction on tricyclics was 48%, versus 28% on placebo. For SSRIs and SNRIs, the fractions of people experiencing a 30% pain reduction were 36% (20% in the placebo comparator arms) and 42% (32% in the corresponding placebo comparator arms) respectively. Discontinuation of treatment due to side effects was common.[64] Antidepressants including amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, and pirlindole are recommended by the European League Against Rheumatism (EULAR) for the treatment of fibromyalgia based on "limited evidence".[65]

Neuropathic pain

A 2014 meta-analysis from the Cochrane Collaboration found the antidepressant duloxetine to be effective for the treatment of pain resulting from diabetic neuropathy.[66] The same group reviewed data for amitriptyline in the treatment of neuropathic pain and found limited useful randomized clinical trial data. They concluded that the long history of successful use in the community for the treatment of fibromyalgia and neuropathic pain justified its continued use.[67] The group was concerned about the potential overestimation of the amount of pain relief provided by amitriptyline, and highlighted that only a small number of people will experience significant pain relief by taking this medication.[67]

Other uses

Antidepressants may be modestly helpful for treating people who have both depression and alcohol dependence, however, the evidence supporting this association is of low quality.[68] Bupropion is used to help people stop smoking. Antidepressants are also used to control some symptoms of narcolepsy.[69] Antidepressants may be used to relieve pain in people with active rheumatoid arthritis. However, further research is required.[70] Antidepressants have been shown to be superior to placebo in treating depression in individuals with physical illness, although reporting bias may have exaggerated this finding.[71]

Limitations and strategies

Among individuals treated with a given antidepressant, between 30% and 50% do not show a response.[72][73] Approximately one-third of people achieve a full remission, one-third experience a response, and one-third are non-responders. Partial remission is characterized by the presence of poorly defined residual symptoms. These symptoms typically include depressed mood, anxiety, sleep disturbance, fatigue, and diminished interest or pleasure. It is currently unclear which factors predict partial remission. However, it is clear that residual symptoms are powerful predictors of relapse, with relapse rates three to six times higher in people with residual symptoms than in those, who experience full remission.[74] In addition, antidepressant drugs tend to lose efficacy throughout long-term maintenance therapy.[75] According to data from the Centers for Disease Control and Prevention, less than one-third of Americans taking one antidepressant medication have seen a mental health professional in the previous year.[76] Several strategies are used in clinical practice to try to overcome these limits and variations.[77] They include switching medication, augmentation, and combination.

There is controversy amongst researchers regarding the efficacy and risk-benefit ratio of antidepressants.[78][79] Although antidepressants consistently out-perform a placebo in meta-analyses, the difference is modest and it is not clear that their statistical superiority results in clinical efficacy.[20][80][81][82] The aggregate effect of antidepressants typically results in changes below the threshold of clinical significance on depression rating scales.[83][84] Proponents of antidepressants counter that the most common scale, the HDRS, is not suitable for assessing drug action, that the threshold for clinical significance is arbitrary, and that antidepressants consistently result in significantly raised scores on the mood item of the scale.[85] Assessments of antidepressants using alternative, more sensitive scales, such as the MADRS, do not result in marked difference from the HDRS and likewise only find a marginal clinical benefit.[86] Another hypothesis proposed to explain the poor performance of antidepressants in clinical trials is a high treatment response heterogeneity. Some patients, that differ strongly in their response to antidepressants, could influence the average response, while the heterogeneity could itself be obscured by the averaging. Studies have not supported this hypothesis, but it is very difficult to measure treatment effect heterogeneity.[87] Poor and complex clinical trial design might also account for the small effects seen for antidepressants.[88][89] The randomized controlled trials used to approve drugs are short, and may not capture the full effect of antidepressants.[89] Additionally, the placebo effect might be inflated in these trials by frequent clinical consultation, lowering the comparative performance of antidepressants.[89] Critics agree that current clinical trials are poorly-designed, which limits the knowledge on antidepressant.[90] More naturalistic studies, such as STAR*D, have produced results, which suggest that antidepressants may be less effective in clinical practice than in randomized controlled trials.[91][92]

Critics of antidepressants maintain that the superiority of antidepressants over placebo is the result of systemic flaws in clinical trials and the research literature.[91][83] Trials conducted with industry involvement tend to produce more favorable results, and accordingly many of the trials included in meta-analyses are at high risk of bias.[93][83] Additionally, meta-analyses co-authored by industry employees find more favorable results for antidepressants.[83] The results of antidepressant trials are significantly more likely to be published if they are favorable, and unfavorable results are very often left unpublished or misreported, a phenomenon called publication bias or selective publication.[94] Although this issue has diminished with time, it remains an obstacle to accurately assessing the efficacy of antidepressants.[95] Misreporting of clinical trial outcomes and of serious adverse events, such as suicide, is common.[96][93][97] Ghostwriting of antidepressant trials is widespread, a practice in which prominent researchers, or so-called key opinion leaders, attach their names to studies actually written by pharmaceutical company employees or consultants.[97] A particular concern is that the psychoactive effects of antidepressants may lead to the unblinding of participants or researchers, enhancing the placebo effect and biasing results.[44][98][93] Some have therefore maintained that antidepressants may only be active placebos.[91][83] When these and other flaws in the research literature are not taken into account, meta-analyses may find inflated results on the basis of poor evidence.[93]

Critics contend that antidepressants have not been proven sufficiently effective by RCTs or in clinical practice and that the widespread use of antidepressants is not evidence-based.[91][83] They also note that adverse effects, including withdrawal difficulties, are likely underreported, skewing clinicians' ability to make risk-benefit judgements.[79][99][100][91] Accordingly, they believe antidepressants are overused, particularly for non-severe depression and conditions in which they are not indicated.[79][101] Critics charge that the widespread use and public acceptance of antidepressants is the result of pharmaceutical advertising, research manipulation, and misinformation.[102][103][104][105]

Current mainstream psychiatric opinion recognizes the limitations of antidepressants but recommends their use in adults with more severe depression as a first-line treatment.[106][107]

Switching antidepressants

The American Psychiatric Association 2000 Practice Guideline advises that where no response is achieved within the following six to eight weeks of treatment with an antidepressant, switch to an antidepressant in the same class, and then to a different class. A 2006 meta-analysis review found wide variation in the findings of prior studies: for people who had failed to respond to an SSRI antidepressant, between 12% and 86% showed a response to a new drug. However, the more antidepressants an individual had previously tried, the less likely they were to benefit from a new antidepressant trial.[73] However, a later meta-analysis found no difference between switching to a new drug and staying on the old medication: although 34% of treatment-resistant people responded when switched to the new drug, 40% responded without being switched.[108]

Augmentation and combination

For a partial response, the American Psychiatric Association (APA) guidelines suggest augmentation or adding a drug from a different class. These include lithium and thyroid augmentation, dopamine agonists, sex steroids, NRIs, glucocorticoid-specific agents, or the newer anticonvulsants.[109]

A combination strategy involves adding another antidepressant, usually from a different class to affect other mechanisms. Although this may be used in clinical practice, there is little evidence for the relative efficacy or adverse effects of this strategy.[110] Other tests conducted include the use of psychostimulants as an augmentation therapy. Several studies have shown the efficacy of combining modafinil for treatment-resistant people. It has been used to help combat SSRI-associated fatigue.[111]

Long-term use and stopping

The effects of antidepressants typically do not continue once the course of medication ends. This results in a high rate of relapse. In 2003, a meta-analysis found that 18% of people who had responded to an antidepressant relapsed while still taking it, compared to 41% whose antidepressant was switched for a placebo.[112]

A gradual loss of therapeutic benefit occurs in a minority of people during the course of treatment.[113][114] A strategy involving the use of pharmacotherapy in the treatment of the acute episode, followed by psychotherapy in its residual phase, has been suggested by some studies.[115][116] For patients who wish to stop their antidepressants, engaging in brief psychological interventions such as Preventive Cognitive Therapy[117] or mindfulness-based cognitive therapy while tapering down has been found to diminish the risk for relapse.[118]

Adverse effects

Antidepressants can cause various adverse effects, depending on the individual and the drug in question.[119]

Almost any medication involved with serotonin regulation has the potential to cause serotonin toxicity (also known as serotonin syndrome) — an excess of serotonin that can induce mania, restlessness, agitation, emotional lability, insomnia, and confusion as its primary symptoms.[120][121] Although the condition is serious, it is not particularly common, generally only appearing at high doses or while on other medications. Assuming proper medical intervention has been taken (within about 24 hours) it is rarely fatal.[122][123] Antidepressants appear to increase the risk of diabetes by about 1.3-fold.[124]

MAOIs tend to have pronounced (sometimes fatal) interactions with a wide variety of medications and over-the-counter drugs. If taken with foods that contain very high levels of tyramine (e.g., mature cheese, cured meats, or yeast extracts), they may cause a potentially lethal hypertensive crisis. At lower doses, the person may only experience a headache due to an increase in blood pressure.[125]

In response to these adverse effects, a different type of MAOI, the class of reversible inhibitor of monoamine oxidase A (RIMA), has been developed. The primary advantage of RIMAs is that they do not require the person to follow a special diet while being purportedly effective as SSRIs and tricyclics in treating depressive disorders.[126]

Tricyclics and SSRI can cause the so-called drug-induced QT prolongation, especially in older adults;[127] this condition can degenerate into a specific type of abnormal heart rhythm called Torsades de points, which can potentially lead to sudden cardiac arrest.[128]

Some antidepressants are also believed to increase thoughts of suicidal ideation.

Antidepressants have been associated with an increased risk of dementia in older adults.[129]

Pregnancy

SSRI use in pregnancy has been associated with a variety of risks with varying degrees of proof of causation. As depression is independently associated with negative pregnancy outcomes, determining the extent to which observed associations between antidepressant use and specific adverse outcomes reflect a causative relationship has been difficult in some cases.[130] In other cases, the attribution of adverse outcomes to antidepressant exposure seems fairly clear.

SSRI use in pregnancy is associated with an increased risk of spontaneous abortion of about 1.7-fold,[131][132] and is associated with preterm birth and low birth weight.[133]

A systematic review of the risk of major birth defects in antidepressant-exposed pregnancies found a small increase (3% to 24%) in the risk of major malformations and a risk of cardiovascular birth defects that did not differ from non-exposed pregnancies.[134] A study of fluoxetine-exposed pregnancies found a 12% increase in the risk of major malformations that did not reach statistical significance.[135] Other studies have found an increased risk of cardiovascular birth defects among depressed mothers not undergoing SSRI treatment, suggesting the possibility of ascertainment bias, e.g. that worried mothers may pursue more aggressive testing of their infants.[136] Another study found no increase in cardiovascular birth defects and a 27% increased risk of major malformations in SSRI exposed pregnancies.[132] The FDA advises for the risk of birth defects with the use of paroxetine[137] and the MAOI should be avoided.

A 2013 systematic review and meta-analysis found that antidepressant use during pregnancy was statistically significantly associated with some pregnancy outcomes, such as gestational age and preterm birth, but not with other outcomes. The same review cautioned that because differences between the exposed and unexposed groups were small, it was doubtful whether they were clinically significant.[138]

A neonate (infant less than 28 days old) may experience a withdrawal syndrome from abrupt discontinuation of the antidepressant at birth. Antidepressants can be present in varying amounts in breast milk, but their effects on infants are currently unknown.[139]

Moreover, SSRIs inhibit nitric oxide synthesis, which plays an important role in setting the vascular tone. Several studies have pointed to an increased risk of prematurity associated with SSRI use, and this association may be due to an increased risk of pre-eclampsia during pregnancy.[140]

Antidepressant-induced mania

Another possible problem with antidepressants is the chance of antidepressant-induced mania or hypomania in people with or without a diagnosis of bipolar disorder. Many cases of bipolar depression are very similar to those of unipolar depression. Therefore, the person can be misdiagnosed with unipolar depression and be given antidepressants. Studies have shown that antidepressant-induced mania can occur in 20–40% of people with bipolar disorder.[141] For bipolar depression, antidepressants (most frequently SSRIs) can exacerbate or trigger symptoms of hypomania and mania.[142] Bupropion has been associated with a lower risk of mood switch than other antidepressants.[143]

Suicide

Main page: Chemistry:Antidepressants and suicide risk

Studies have shown that the use of antidepressants is correlated with an increased risk of suicidal behavior and thinking (suicidality) in those aged under 25 years old.[144] This problem has been serious enough to warrant government intervention by the US Food and Drug Administration (FDA) to warn of the increased risk of suicidality during antidepressant treatment.[145] According to the FDA, the heightened risk of suicidality occurs within the first one to two months of treatment.[146][147] The National Institute for Health and Care Excellence (NICE) places the excess risk in the "early stages of treatment".[148] A meta-analysis suggests that the relationship between antidepressant use and suicidal behavior or thoughts is age-dependent.[144] Compared with placebo, the use of antidepressants is associated with an increase in suicidal behavior or thoughts among those 25 years old or younger (OR=1.62). A review of RCTs and epidemiological studies by Healy and Whitaker found an increase in suicidal acts by a factor of 2.4.[149] There is no effect or possibly a mild protective effect among those aged 25 to 64 (OR=0.79). Antidepressant treatment has a protective effect against suicidality among those aged 65 and over (OR=0.37).[144][150]

Sexual dysfunction

Sexual side effects are also common with SSRIs, such as loss of sexual drive, failure to reach orgasm, and erectile dysfunction.[151] Although usually reversible, these sexual side-effects can, in rare cases, continue after the drug has been completely withdrawn.[152][153]

In a study of 1,022 outpatients, overall sexual dysfunction with all antidepressants averaged 59.1%[154] with SSRI values between 57% and 73%, mirtazapine 24%, nefazodone 8%, amineptine 7%, and moclobemide 4%. Moclobemide, a selective reversible MAO-A inhibitor, does not cause sexual dysfunction[155] and can lead to an improvement in all aspects of sexual function.[156]

Biochemical mechanisms suggested as causative include increased serotonin, particularly affecting 5-HT2 and 5-HT3 receptors; decreased dopamine; decreased norepinephrine; blockade of cholinergic and α1adrenergic receptors; inhibition of nitric oxide synthetase; and elevation of prolactin levels.[157] Mirtazapine is reported to have fewer sexual side effects, most likely because it antagonizes 5-HT2 and 5-HT3 receptors and may, in some cases, reverse sexual dysfunction induced by SSRIs by the same mechanism.[158]

Bupropion, a weak NDRI and nicotinic antagonist, may be useful in treating reduced libido as a result of SSRI treatment.[159]

Emotional blunting

Certain antidepressants may cause emotional blunting, characterized by a reduced intensity of both positive and negative emotions as well as symptoms of apathy, indifference, and amotivation.[160][161][162][163][164][165][166][167][168] It may be experienced as either beneficial or detrimental depending on the situation.[169] This side effect has been particularly associated with serotonergic antidepressants like SSRIs and SNRIs but may be less with atypical antidepressants like bupropion, agomelatine, and vortioxetine.[161][167][170][171] Higher doses of antidepressants seem to be more likely to produce emotional blunting than lower doses.[161] Emotional blunting can be decreased by reducing dosage, discontinuing the medication, or switching to a different antidepressant that may have less propensity for causing this side effect.[161]

Changes in weight

Changes in appetite or weight are common among antidepressants but are largely drug-dependent and related to which neurotransmitters they affect. Mirtazapine and paroxetine, for example, may be associated with weight gain and/or increased appetite,[172][173][174] while others (such as bupropion and venlafaxine) achieve the opposite effect.[175][176]

The antihistaminic properties of certain TCA- and TeCA-class antidepressants have been shown to contribute to the common side effects of increased appetite and weight gain associated with these classes of medication.

Bone loss

A 2021 nationwide cohort study in South Korea observed a link between SSRI use and bone loss, particularly in recent users. The study also stressed the need of further research to better understand these effects.[177] A 2012 review found that SSRIs along with tricyclic antidepressants were associated with a significant increase in the risk of osteoporotic fractures, peaking in the months after initiation, and moving back towards baseline during the year after treatment was stopped. These effects exhibited a dose–response relationship within SSRIs which varied between different drugs of that class.[178] A 2018 meta-analysis of 11 small studies found a reduction in bone density of the lumbar spine in SSRI users which affected older people the most.[179]

Risk of death

A 2017 meta-analysis found that antidepressants were associated with a significantly increased risk of death (+33%) and new cardiovascular complications (+14%) in the general population.[180] Conversely, risks were not greater in people with existing cardiovascular disease.[180]

Discontinuation syndrome

Main page: Medicine:Antidepressant discontinuation syndrome

Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication.[181] The symptoms may include flu-like symptoms, trouble sleeping, nausea, poor balance, sensory changes, and anxiety.[181][13][182] The problem usually begins within three days and may last for several months.[181][182] Rarely psychosis may occur.[181]

A discontinuation syndrome can occur after stopping any antidepressant including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs).[181][13] The risk is greater among those who have taken the medication for longer and when the medication in question has a short half-life.[181] The underlying reason for its occurrence is unclear.[181] The diagnosis is based on the symptoms.[181]

Methods of prevention include gradually decreasing the dose among those who wish to stop, though it is possible for symptoms to occur with tapering.[181][12][182] Treatment may include restarting the medication and slowly decreasing the dose.[181] People may also be switched to the long-acting antidepressant fluoxetine, which can then be gradually decreased.[12]

Approximately 20–50% of people who suddenly stop an antidepressant develop an antidepressant discontinuation syndrome.[181][13][182] The condition is generally not serious.[181] Though about half of people with symptoms describe them as severe.[182] Some restart antidepressants due to the severity of the symptoms.[182]

Pharmacology

Main page: Chemistry:Pharmacology of antidepressants

Antidepressants act via a large number of different mechanisms of action.[183][184][185] This includes serotonin reuptake inhibition (SSRIs, SNRIs, TCAs, vilazodone, vortioxetine), norepinephrine reuptake inhibition (NRIs, SNRIs, TCAs), dopamine reuptake inhibition (bupropion, amineptine, nomifensine), direct modulation of monoamine receptors (vilazodone, vortioxetine, SARIs, agomelatine, TCAs, TeCAs, antipsychotics), monoamine oxidase inhibition (MAOIs), and NMDA receptor antagonism (ketamine, esketamine, dextromethorphan), among others (e.g., brexanolone, tianeptine).[183][184][185] Some antidepressants also have additional actions, like sigma receptor modulation (certain SSRIs, TCAs, dextromethorphan) and antagonism of histamine H1 and muscarinic acetylcholine receptors (TCAs, TeCAs).[186][185]

The earliest and most widely known scientific theory of antidepressant action is the monoamine hypothesis, which can be traced back to the 1950s and 1960s.[187][188] This theory states that depression is due to an imbalance, most often a deficiency, of the monoamine neurotransmitters, namely serotonin, norepinephrine, and/or dopamine.[187][188] However, serotonin in particular has been implicated, as in the serotonin hypothesis of depression.[189] The monoamine hypothesis was originally proposed based on observations that reserpine, a drug which depletes the monoamine neurotransmitters, produced depressive effects in people,[188] and that certain hydrazine antituberculosis agents like iproniazid, which prevent the breakdown of monoamine neurotransmitters, produced apparent antidepressant effects.[187] Most currently marketed antidepressants, which are monoaminergic in their actions, are theoretically consistent with the monoamine hypothesis.[187] Despite the widespread nature of the monoamine hypothesis, it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, many people with depression do not respond to monoaminergic antidepressants.[190][191] A number of alternative hypotheses have been proposed, including hypotheses involving glutamate, neurogenesis, epigenetics, cortisol hypersecretion, and inflammation, among others.[190][191][192][193]

In 2022, a major systematic umbrella review by Joanna Moncrieff and colleagues showed that the serotonin theory of depression was not supported by evidence from a wide variety of areas.[189] The authors concluded that there is no association between serotonin and depression, and that there is no evidence that strongly supports the theory that depression is caused by low serotonin activity or concentrations.[189] Other literature had described the lack of support for the theory previously.[102][103][105] In many of the expert responses to the review, it was stated that the monoamine hypothesis had already long been abandoned by psychiatry.[194][195] This is in spite of about 90% of the general public in Western countries believing the theory to be true and many in the field of psychiatry continuing to promote the theory up to recent times.[195][105] In addition to the serotonin umbrella review, reviews have found that reserpine, a drug that depletes the monoamine neurotransmitters—including serotonin, norepinephrine, and dopamine—shows no consistent evidence of producing depressive effects.[188][196] Instead, findings of reserpine and mood are highly mixed, with similar proportions of studies finding that it has no influence on mood, produces depressive effects, or actually has antidepressant effects.[196] In relation to this, the general monoamine hypothesis, as opposed to only the serotonin theory of depression, likewise does not appear to be well-supported by evidence.[188][196][105]

The serotonin and monoamine hypotheses of depression have been heavily promoted by the pharmaceutical industry (e.g., in advertisements) and by the psychiatric profession at large despite the lack of evidence in support of them.[102][103][188][197][105][104] In the case of the pharmaceutical industry, this can be attributed to obvious financial incentives, with the theory creating a bias against non-pharmacological treatments for depression.[104][102][103][188]

An alternative theory for antidepressant action proposed by certain academics such as Irving Kirsch and Joanna Moncrieff is that they work largely or entirely via placebo mechanisms.[44][98][198][199] This is supported by meta-analyses of randomized controlled trials of antidepressants for depression, which consistently show that placebo groups in trials improve about 80 to 90% as much as antidepressant groups on average[44][200] and that antidepressants are only marginally more effective for depression than placebos.[93][86][201][80][81] The difference between antidepressants and placebo corresponds to an effect size (SMD) of about 0.3, which in turn equates to about a 2- to 3-point additional improvement on the 0–52-point (HRSD) and 0–60-point (MADRS) depression rating scales used in trials.[93][86][201][80][81] Differences in effectiveness between different antidepressants are small and not clinically meaningful.[202][201] The small advantage of antidepressants over placebo is often statistically significant and is the basis for their regulatory approval, but is sufficiently modest that its clinical significance is doubtful.[84][203][86][81] Moreover, the small advantage of antidepressants over placebo may simply be a methodological artifact caused by unblinding due to the psychoactive effects and side effects of antidepressants, in turn resulting in enhanced placebo effects and apparent antidepressant efficacy.[44][81][98] Placebos have been found to modify the activity of several brain regions and to increase levels of dopamine and endogenous opioids in the reward pathways.[204][205][206] It has been argued by Kirsch that although antidepressants may be used efficaciously for depression as active placebos, they are limited by significant pharmacological side effects and risks, and therefore non-pharmacological therapies, such as psychotherapy and lifestyle changes, which can have similar efficacy to antidepressants but do not have their adverse effects, ought to be preferred as treatments in people with depression.[83]

The placebo response, or the improvement in scores in the placebo group in clinical trials, is not only due to the placebo effect, but is also due to other phenomena such as spontaneous remission and regression to the mean.[44][207] Depression tends to have an episodic course, with people eventually recovering even with no medical intervention, and people tend to seek treatment, as well as enroll in clinical trials, when they are feeling their worst.[97][207] In meta-analyses of trials of depression therapies, Kirsch estimated based on improvement in untreated waiting-list controls that spontaneous remission and regression to the mean only account for about 25% of the improvement in depression scores with antidepressant therapy.[44][208][209][210][97] However, another academic, Michael P. Hengartner, has argued and presented evidence that spontaneous remission and regression to the mean might actually account for most of the improvement in depression scores with antidepressants, and that the substantial placebo effect observed in clinical trials might largely be a methodological artifact.[207] This suggests that antidepressants may be associated with much less genuine treatment benefit, whether due to the placebo effect or to the antidepressant itself, than has been traditionally assumed.[207]

Types

Selective serotonin reuptake inhibitors

refer to caption
Blister pack of Prozac (fluoxetine), a selective serotonin reuptake inhibitor

Selective serotonin reuptake inhibitors (SSRIs) are believed to increase the extracellular level of the neurotransmitter serotonin by limiting its reabsorption into the presynaptic cell, increasing the level of serotonin in the synaptic cleft available to bind to the postsynaptic receptor. They have varying degrees of selectivity for the other monoamine transporters, with pure SSRIs having only weak affinity for the norepinephrine and dopamine transporters.

SSRIs are the most widely prescribed antidepressants in many countries.[211] The efficacy of SSRIs in mild or moderate cases of depression has been disputed.[212][213][214][215]

Serotonin–norepinephrine reuptake inhibitors

chemical structure of the SNRI drug venlafaxine
The chemical structure of venlafaxine (Effexor), an SNRI

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are potent inhibitors of the reuptake of serotonin and norepinephrine. These neurotransmitters are known to play an important role in mood. SNRIs can be contrasted with the more widely used selective serotonin reuptake inhibitors (SSRIs), which act mostly upon serotonin alone.

The human serotonin transporter (SERT) and norepinephrine transporter (NET) are membrane proteins that are responsible for the reuptake of serotonin and norepinephrine. Balanced dual inhibition of monoamine reuptake may offer advantages over other antidepressants drugs by treating a wider range of symptoms.[216]

SNRIs are sometimes also used to treat anxiety disorders, obsessive–compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), chronic neuropathic pain, and fibromyalgia syndrome (FMS), and for the relief of menopausal symptoms.

Serotonin modulators and stimulators

Serotonin modulator and stimulators (SMSs), sometimes referred to more simply as "serotonin modulators", are a type of drug with a multimodal action specific to the serotonin neurotransmitter system. To be precise, SMSs simultaneously modulate one or more serotonin receptors and inhibit the reuptake of serotonin. The term was coined in reference to the mechanism of action of the serotonergic antidepressant vortioxetine, which acts as a serotonin reuptake inhibitor (SRI), a partial agonist of the 5-HT1A receptor, and antagonist of the 5-HT3 and 5-HT7 receptors.[217][218][219] However, it can also technically be applied to vilazodone, which is an antidepressant as well and acts as an SRI and 5-HT1A receptor partial agonist.[220]

An alternative term is serotonin partial agonist/reuptake inhibitor (SPARI), which can be applied only to vilazodone.[221]

Serotonin antagonists and reuptake inhibitors

Serotonin antagonist and reuptake inhibitors (SARIs) while mainly used as antidepressants are also anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also act as α1-adrenergic receptor antagonists. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds. They include trazodone and nefazodone.

Tricyclic antidepressants

The majority of the tricyclic antidepressants (TCAs) act primarily as serotonin–norepinephrine reuptake inhibitors (SNRIs) by blocking the serotonin transporter (SERT) and the norepinephrine transporter (NET), respectively, which results in an elevation of the synaptic concentrations of these neurotransmitters, and therefore an enhancement of neurotransmission.[222][223] Notably, with the sole exception of amineptine, the TCAs have weak affinity for the dopamine transporter (DAT), and therefore have low efficacy as dopamine reuptake inhibitors (DRIs).[222]

Although TCAs are sometimes prescribed for depressive disorders, they have been largely replaced in clinical use in most parts of the world by newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and norepinephrine reuptake inhibitors (NRIs). Adverse effects have been found to be of a similar level between TCAs and SSRIs.[224]

Tetracyclic antidepressants

Tetracyclic antidepressants (TeCAs) are a class of antidepressants that were first introduced in the 1970s. They are named after their chemical structure, which contains four rings of atoms, and are closely related to tricyclic antidepressants (TCAs), which contain three rings of atoms.

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors (MAOIs) are chemicals that inhibit the activity of the monoamine oxidase enzyme family. They have a long history of use as medications prescribed for the treatment of depression. They are particularly effective in treating atypical depression.[225] They are also used in the treatment of Parkinson's disease and several other disorders.

Because of potentially lethal dietary and drug interactions, MAOIs have historically been reserved as a last line of treatment, used only when other classes of antidepressant drugs (for example selective serotonin reuptake inhibitors and tricyclic antidepressants) have failed.[226]

MAOIs have been found to be effective in the treatment of panic disorder with agoraphobia,[227] social phobia,[228][229][230] atypical depression[231][232] or mixed anxiety and depression, bulimia,[233][234][235][236] and post-traumatic stress disorder,[237] as well as borderline personality disorder.[238] MAOIs appear to be particularly effective in the management of bipolar depression according to a retrospective-analysis.[239] There are reports of MAOI efficacy in obsessive–compulsive disorder (OCD), trichotillomania, dysmorphophobia, and avoidant personality disorder, but these reports are from uncontrolled case reports.[240]

MAOIs can also be used in the treatment of Parkinson's disease by targeting MAO-B in particular (therefore affecting dopaminergic neurons), as well as providing an alternative for migraine prophylaxis. Inhibition of both MAO-A and MAO-B is used in the treatment of clinical depression and anxiety disorders.

NMDA receptor antagonists

NMDA receptor antagonists like ketamine and esketamine are rapid-acting antidepressants and seem to work via blockade of the ionotropic glutamate NMDA receptor.[241] Other NMDA antagonists may also play a role in treating depression. The combination medication dextromethorphan/bupropion (Auvelity), which contains the NMDA receptor antagonist dextromethorphan, was approved in the United States in 2022 for treating major depressive disorder.[242][243]

Others

See the list of antidepressants and management of depression for other drugs that are not specifically characterized.

Adjuncts

Adjunct medications are an umbrella category of substances that increase the potency or "enhance" antidepressants.[244] They work by affecting variables very close to the antidepressant, sometimes affecting a completely different mechanism of action. This may be attempted when depression treatments have not been successful in the past.

Common types of adjunct medication techniques generally fall into the following categories:

  • Two or more antidepressants taken together
    • From the same class (affecting the same area of the brain, often at a much higher level)
    • From different classes (affecting multiple parts of the brain not covered simultaneously by either drug alone)
  • An antipsychotic combined with an antidepressant, particularly atypical antipsychotics such as aripiprazole (Abilify), quetiapine (Seroquel), olanzapine (Zyprexa), and risperidone (Risperdal).[245]

It is unknown if undergoing psychological therapy at the same time as taking anti-depressants enhances the anti-depressive effect of the medication.[246]

Less common adjuncts

Lithium has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone.[247] Furthermore, Lithium dramatically decreases the suicide risk in recurrent depression.[248] There is some evidence for the addition of a thyroid hormone, triiodothyronine, in patients with normal thyroid function.[249]

Psychopharmacologists have also tried adding a stimulant, in particular, D-amphetamine.[250] However, the use of stimulants in cases of treatment-resistant depression is relatively controversial.[251][252] A review article published in 2007 found psychostimulants may be effective in treatment-resistant depression with concomitant antidepressant therapy, but a more certain conclusion could not be drawn due to substantial deficiencies in the studies available for consideration, and the somewhat contradictory nature of their results.[252]

History

refer to caption
St John's wort

The idea of an antidepressant, at least if melancholy is thought synonymous with the depression, is at least since the publication of the 1599 pamphlet A pil to purge melancholie or, A preprative to a pvrgation: or, Topping, copping, and capping: take either or whether: or, Mash them, and squash them, and dash them, and diddle come derrie come daw them, all together.., after to this Thomas d'Urfey's Wit and Mirth: Or Pills to Purge Melancholy, the title of a large collection of songs, was published between 1698 and 1720.

Before the 1950s, opioids and amphetamines were commonly used as antidepressants.[253][254] Their use was later restricted due to their addictive nature and side effects.[253] Extracts from the herb St John's wort have been used as a "nerve tonic" to alleviate depression.[255]

St John's wort fell out of favor in most countries through the 19th and 20th centuries, except in Germany , where Hypericum extracts were eventually licensed, packaged, and prescribed. Small-scale efficacy trials were carried out in the 1970s and 1980s, and attention grew in the 1990s following a meta-analysis.[256] It remains an over-the-counter drug (OTC) supplement in most countries. Lead contamination associated with its usage has been seen as concerning, as lead levels in women in the United States taking St. John's wort are elevated by about 20% on average.[257] Research continues to investigate its active component hyperforin, and to further understand its mode of action.[258][259]

Isoniazid, iproniazid, and imipramine

In 1951, Irving Selikoff and Edward H. Robitzek, working out of Sea View Hospital on Staten Island, began clinical trials on two new anti-tuberculosis agents developed by Hoffman-LaRoche, isoniazid, and iproniazid. Only patients with a poor prognosis were initially treated. Nevertheless, their condition improved dramatically. Selikoff and Robitzek noted "a subtle general stimulation ... the patients exhibited renewed vigor and indeed this occasionally served to introduce disciplinary problems."[260] The promise of a cure for tuberculosis in the Sea View Hospital trials was excitedly discussed in the mainstream press.

In 1952, learning of the stimulating side effects of isoniazid, the Cincinnati psychiatrist Max Lurie tried it on his patients. In the following year, he and Harry Salzer reported that isoniazid improved depression in two-thirds of their patients, so they then coined the term antidepressant to refer to its action.[261] A similar incident took place in Paris, where Jean Delay, head of psychiatry at Sainte-Anne Hospital, heard of this effect from his pulmonology colleagues at Cochin Hospital. In 1952 (before Lurie and Salzer), Delay, with the resident Jean-Francois Buisson, reported the positive effect of isoniazid on depressed patients.[262] The mode of antidepressant action of isoniazid is still unclear. It is speculated that its effect is due to the inhibition of diamine oxidase, coupled with a weak inhibition of monoamine oxidase A.[263]

Selikoff and Robitzek also experimented with another anti-tuberculosis drug, iproniazid; it showed a greater psychostimulant effect, but more pronounced toxicity.[264] Later, Jackson Smith, Gordon Kamman, George E. Crane, and Frank Ayd, described the psychiatric applications of iproniazid. Ernst Zeller found iproniazid to be a potent monoamine oxidase inhibitor.[265] Nevertheless, iproniazid remained relatively obscure until Nathan S. Kline, the influential head of research at Rockland State Hospital, began to popularize it in the medical and popular press as a "psychic energizer".[265][266] Roche put a significant marketing effort behind iproniazid.[265] Its sales grew until it was recalled in 1961, due to reports of lethal hepatotoxicity.[265]

The antidepressant effect of a tricyclic, a three-ringed compound, was first discovered in 1957 by Roland Kuhn in a Swiss psychiatric hospital. Antihistamine derivatives were used to treat surgical shock and later as neuroleptics. Although in 1955, reserpine was shown to be more effective than a placebo in alleviating anxious depression, neuroleptics were being developed as sedatives and antipsychotics.

Attempting to improve the effectiveness of chlorpromazine, Kuhn — in conjunction with the Geigy Pharmaceutical Company — discovered the compound "G 22355", later renamed imipramine. Imipramine had a beneficial effect on patients with depression who showed mental and motor retardation. Kuhn described his new compound as a "thymoleptic" "taking hold of the emotions," in contrast with neuroleptics, "taking hold of the nerves" in 1955–56. These gradually became established, resulting in the patent and manufacture in the US in 1951 by Häfliger and SchinderA.[267]

Antidepressants became prescription drugs in the 1950s. It was estimated that no more than fifty to one hundred individuals per million had the kind of depression that these new drugs would treat, and pharmaceutical companies were not enthusiastic about marketing for this small market. Sales through the 1960s remained poor compared to the sales of tranquilizers,[268][unreliable medical source?] which were being marketed for different uses.[269] Imipramine remained in common use and numerous successors were introduced. The use of monoamine oxidase inhibitors (MAOI) increased after the development and introduction of "reversible" forms affecting only the MAO-A subtype of inhibitors, making this drug safer to use.[269][270]

By the 1960s, it was thought that the mode of action of tricyclics was to inhibit norepinephrine reuptake. However, norepinephrine reuptake became associated with stimulating effects. Later tricyclics were thought to affect serotonin as proposed in 1969 by Carlsson and Lindqvist as well as Lapin and Oxenkrug.

Second-generation antidepressants

Researchers began a process of rational drug design to isolate antihistamine-derived compounds that would selectively target these systems. The first such compound to be patented was zimelidine in 1971, while the first released clinically was indalpine. Fluoxetine was approved for commercial use by the US Food and Drug Administration (FDA) in 1988, becoming the first blockbuster SSRI. Fluoxetine was developed at Eli Lilly and Company in the early 1970s by Bryan Molloy, Klaus Schmiegel, David T. Wong, and others.[271][272] SSRIs became known as "novel antidepressants" along with other newer drugs such as SNRIs and NRIs with various selective effects.[273]

Rapid-acting antidepressants

Esketamine (brand name Spravato), the first rapid-acting antidepressant to be approved for clinical treatment of depression, was introduced for this indication in March 2019 in the United States.[241]

Research

A 2016 randomized controlled trial evaluated the rapid antidepressant effects of the psychedelic Ayahuasca in treatment-resistant depression with a positive outcome.[274][275] In 2018, the FDA granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatment-resistant depression and in 2019, the FDA granted Breakthrough Therapy Designation for psilocybin therapy treating major depressive disorder.[276]

Publication bias and aged research

A 2018 systematic review published in The Lancet comparing the efficacy of 21 different first and second generation antidepressants found that antidepressant drugs tended to perform better and cause less adverse events when they were novel or experimental treatments compared to when they were evaluated again years later.[277] Unpublished data was also associated with smaller positive effect sizes. However, the review did not find evidence of bias associated with industry funded research.

Society and culture

Prescription trends

United Kingdom

In the UK, figures reported in 2010 indicated that the number of antidepressants prescribed by the National Health Service (NHS) almost doubled over a decade.[278] Further analysis published in 2014 showed that number of antidepressants dispensed annually in the community went up by 25 million in the 14 years between 1998 and 2012, rising from 15 million to 40 million. Nearly 50% of this rise occurred in the four years after the 2008 banking crash, during which time the annual increase in prescriptions rose from 6.7% to 8.5%.[279] These sources also suggest that aside from the recession, other factors that may influence changes in prescribing rates may include: improvements in diagnosis, a reduction of the stigma surrounding mental health, broader prescribing trends, GP characteristics, geographical location, and housing status. Another factor that may contribute to increasing consumption of antidepressants is the fact that these medications now are used for other conditions including social anxiety and post-traumatic stress disorder.

Between 2005 and 2017, the number of adolescents (12 to 17 years) in England who were prescribed antidepressants has doubled. On the other hand, antidepressant prescriptions for children aged 5–11 in England decreased between 1999 and 2017.[280][281] From April 2015, prescriptions increased for both age groups (for people aged 0 to 17) and peaked during the first COVID lockdown in March 2020.[282]

According to National Institute for Health and Care Excellence (NICE) guidelines, antidepressants for children and adolescents with depression and obsessive-compulsive disorder (OCD) should be prescribed together with therapy and after being assessed by a child and adolescent psychiatrist. However, between 2006 and 2017, only 1 in 4 of 12–17 year-olds who were prescribed an SSRI by their GP had seen a specialist psychiatrist and 1 in 6 has seen a pediatrician. Half of these prescriptions were for depression and 16% for anxiety, the latter not being licensed for treatment with antidepressants.[42][283] Among the suggested possible reasons why GPs are not following the guidelines are the difficulties of accessing talking therapies, long waiting lists, and the urgency of treatment.[42][284] According to some researchers, strict adherence to treatment guidelines would limit access to effective medication for young people with mental health problems.[285]

United States

In the United States, antidepressants were the most commonly prescribed medication in 2013.[286] Of the estimated 16 million "long term" (over 24 months) users, roughly 70 percent are female.[286] (As of 2017), about 16.5% of white people in the United States took antidepressants compared with 5.6% of black people in the United States.[287]

Structural formula of the SSRI sertraline

United States: The most commonly prescribed antidepressants in the US retail market in 2010 were:[288]

Drug name Drug class Total prescriptions
Sertraline SSRI 33,409,838
Citalopram SSRI 27,993,635
Fluoxetine SSRI 24,473,994
Escitalopram SSRI 23,000,456
Trazodone SARI 18,786,495
Venlafaxine (all formulations) SNRI 16,110,606
Bupropion (all formulations) NDRI 15,792,653
Duloxetine SNRI 14,591,949
Paroxetine SSRI 12,979,366
Amitriptyline TCA 12,611,254
Venlafaxine XR SNRI 7,603,949
Bupropion XL NDRI 7,317,814
Mirtazapine TeCA 6,308,288
Venlafaxine ER SNRI 5,526,132
Bupropion SR NDRI 4,588,996
Desvenlafaxine SNRI 3,412,354
Nortriptyline TCA 3,210,476
Bupropion ER NDRI 3,132,327
Venlafaxine SNRI 2,980,525
Bupropion NDRI 753,516

Netherlands: In the Netherlands, paroxetine is the most prescribed antidepressant, followed by amitriptyline, citalopram and venlafaxine.[289]

Adherence

Main page: Medicine:Adherence

(As of 2003), worldwide, 30% to 60% of people did not follow their practitioner's instructions about taking their antidepressants,[290] and (As of 2013) in the US, it appeared that around 50% of people did not take their antidepressants as directed by their practitioner.[291]

When people fail to take their antidepressants, there is a greater risk that the drug will not help, that symptoms get worse, that they miss work or are less productive at work, and that the person may be hospitalized.[292]

Social science perspective

Some academics[who?] have highlighted the need to examine the use of antidepressants and other medical treatments in cross-cultural terms, because various cultures prescribe and observe different manifestations, symptoms, meanings, and associations of depression and other medical conditions within their populations.[293][294] These cross-cultural discrepancies, it has been argued, then have implications on the perceived efficacy and use of antidepressants and other strategies in the treatment of depression in these different cultures.[293][294] In India, antidepressants are largely seen as tools to combat marginality, promising the individual the ability to reintegrate into society through their use—a view and association not observed in the West.[293]

Environmental impacts

Because most antidepressants function by inhibiting the reuptake of neurotransmitters serotonin, dopamine, and norepinephrine[295] these drugs can interfere with natural neurotransmitter levels in other organisms impacted by indirect exposure.[296] Antidepressants fluoxetine and sertraline have been detected in aquatic organisms residing in effluent-dominated streams.[297] The presence of antidepressants in surface waters and aquatic organisms has caused concern because ecotoxicological effects on aquatic organisms due to fluoxetine exposure have been demonstrated.[298]

Coral reef fish have been demonstrated to modulate aggressive behavior through serotonin.[299] Artificially increasing serotonin levels in crustaceans can temporarily reverse social status and turn subordinates into aggressive and territorial dominant males.[300]

Exposure to Fluoxetine has been demonstrated to increase serotonergic activity in fish, subsequently reducing aggressive behavior.[301] Perinatal exposure to Fluoxetine at relevant environmental concentrations has been shown to lead to significant modifications of memory processing in 1-month-old cuttlefish.[302] This impairment may disadvantage cuttlefish and decrease their survival. Somewhat less than 10% of orally administered Fluoxetine is excreted from humans unchanged or as glucuronide.[303][304]

See also

References

  1. 1.0 1.1 "Antidepressants". Clinical Psychopharmacology for Neurologists. Springer. 2018. pp. 45–71. doi:10.1007/978-3-319-74604-3_4. ISBN 978-3-319-74602-9. 
  2. Ghaemi, S. Nassir (2019). Clinical Psychopharmacology: Principles and Practice. New York: Oxford University Press. p. 90. ISBN 9780199995486. 
  3. "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". The International Journal of Risk & Safety in Medicine 29 (3–4): 125–134. May 2018. doi:10.3233/JRS-180744. PMID 29733030. 
  4. "Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence". The Open Psychology Journal 1: 42–50. 2008. doi:10.2174/1874350100801010042. 
  5. "Strategies for managing sexual dysfunction induced by antidepressant medication". The Cochrane Database of Systematic Reviews 5 (5): CD003382. May 2013. doi:10.1002/14651858.CD003382.pub3. PMID 23728643. 
  6. "Sexual dysfunction, depression, and the impact of antidepressants". Journal of Clinical Psychopharmacology 29 (2): 157–164. April 2009. doi:10.1097/jcp.0b013e31819c76e9. PMID 19512977. 
  7. Serotonin and noradrenaline reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) – Persistent sexual dysfunction after drug withdrawal (EPITT no 19277), 11 June 20191, EMA/PRAC/265221/2019, Pharmacovigilance Risk Assessment Committee (PRAC)
  8. "SSRI-Induced Indifference". Psychiatry 7 (10): 14–18. October 2010. PMID 21103140. 
  9. "Is your antidepressant making life a little too blah?". Harvard Health Publishing. 8 November 2016. https://www.health.harvard.edu/depression/is-your-antidepressant-making-life-a-little-too-blah. 
  10. "Half of Patients on Antidepressants Experience Emotional Blunting". 19 June 2017. https://www.hcplive.com/view/half-of-patients-on-antidepressants-experience-emotional-blunting. 
  11. "Revisions to Product Labeling". FDA. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf. 
  12. 12.0 12.1 12.2 "A review of the management of antidepressant discontinuation symptoms". Therapeutic Advances in Psychopharmacology 5 (6): 357–368. December 2015. doi:10.1177/2045125315612334. PMID 26834969. 
  13. 13.0 13.1 13.2 13.3 "Antidepressant discontinuation syndrome". CMAJ 189 (21): E747. May 2017. doi:10.1503/cmaj.160991. PMID 28554948. 
  14. 14.0 14.1 "Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials". The British Journal of Psychiatry 208 (2): 114–119. February 2016. doi:10.1192/bjp.bp.114.150136. PMID 26834168. 
  15. 15.0 15.1 "Should antidepressants be used for major depressive disorder?". BMJ Evidence-Based Medicine 25 (4): 130. August 2020. doi:10.1136/bmjebm-2019-111238. PMID 31554608. 
  16. "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis". Lancet 388 (10047): 881–890. August 2016. doi:10.1016/S0140-6736(16)30385-3. PMID 27289172. https://ora.ox.ac.uk/objects/uuid:e0b5ae23-d562-4348-94b8-84f70b7812c5. "When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. All antidepressants were more efficacious than a placebo in adults with major depressive disorder". 
  17. Safer, Daniel; Zito, Julie (2019). "Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns". Frontiers in Psychiatry 10: 705. doi:10.3389/fpsyt.2019.00705. PMID 31681028. 
  18. Hengartner, M. P. (2020). "Editorial: Antidepressant Prescriptions in Children and Adolescents". Frontiers in Psychiatry 11: 600283. doi:10.3389/fpsyt.2020.600283. PMID 33192742. 
  19. 19.0 19.1 "The most effective antidepressants for adults revealed in major review". NIHR Evidence (National Institute for Health and Care Research). 3 April 2018. doi:10.3310/signal-00580. https://evidence.nihr.ac.uk/alert/the-most-effective-antidepressants-for-adults-revealed-in-major-review. 
  20. 20.0 20.1 20.2 20.3 20.4 "Comparative efficacy and acceptability of twenty-one antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251. 
  21. "Antidepressants and the Placebo Effect". Zeitschrift für Psychologie 222 (3): 128–134. January 2014. doi:10.1027/2151-2604/a000176. PMID 25279271. 
  22. "Efficacy of antidepressants". BMJ 336 (7643): 516–517. March 2008. doi:10.1136/bmj.39510.531597.80. PMID 18319297. 
  23. National Collaborating Centre for Mental Health (UK) (2010). Depression: The Treatment and Management of Depression in Adults. National Institute for Health and Clinical Excellence: Guidance (Updated ed.). British Psychological Society. ISBN 978-1-904671-85-5. https://www.ncbi.nlm.nih.gov/books/NBK63748. [page needed]
  24. "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration". PLOS Medicine 5 (2): e45. February 2008. doi:10.1371/journal.pmed.0050045. PMID 18303940. 
  25. Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. Palgrave Macmillan US. 23 April 2015. ISBN 9781137506924. https://play.google.com/store/books/details?id=QYwEogEACAAJ. 
  26. "The serotonin theory of depression: a systematic umbrella review of the evidence". Molecular Psychiatry (Nature Publishing Group) 28 (8): 3243–3256. 20 July 2022. doi:10.1038/s41380-022-01661-0. ISSN 1359-4184. PMID 35854107. 
  27. Has the Serotonin Hypothesis Been Debunked?, 2022, https://www.psychologytoday.com/us/blog/mood-swings/202210/has-the-serotonin-hypothesis-been-debunked, retrieved 2 May 2023 
  28. "Relationship of neurotransmitters to the symptoms of major depressive disorder". The Journal of Clinical Psychiatry 69 (suppl E1): 4–7. 30 April 2008. PMID 18494537. http://www.psychiatrist.com/jcp/article/pages/2008/v69e01/v69e0101.aspx. 
  29. 29.0 29.1 "Depression in adults: treatment and management". 29 June 2022. https://www.nice.org.uk/guidance/ng222/chapter/recommendations. 
  30. Work Group on Major Depressive Disorder (October 2010). "Practice Guideline for the Treatment of Patients With Major Depressive Disorder". American Psychiatric Association. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. 
  31. "Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences". Contemporary Clinical Trials 43: 60–62. July 2015. doi:10.1016/j.cct.2015.05.005. PMID 25979317. 
  32. The Emperor's New Drugs: Exploding the Antidepressant Myth. Basic Books. 2010. pp. 80. ISBN 978-0-465-02016-4. 
  33. "Antidepressants: a triumph of marketing over science?". Prevention and Treatment 5. 2002. doi:10.1037/1522-3736.5.1.525c. 
  34. "Raising questions about antidepressants". Psychotherapy and Psychosomatics 68 (1): 3–14. 1999. doi:10.1159/000012304. PMID 9873236. 
  35. "Prozac may be the best treatment for young people with depression – but more research is needed" (in en). NIHR Evidence (National Institute for Health and Care Research). 12 October 2020. doi:10.3310/alert_41917. https://evidence.nihr.ac.uk/alert/prozac-may-be-the-best-treatment-for-young-people-with-depression-but-more-research-is-needed/. 
  36. "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis". The Lancet. Psychiatry 7 (7): 581–601. July 2020. doi:10.1016/S2215-0366(20)30137-1. PMID 32563306. 
  37. 37.0 37.1 37.2 37.3 "Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment". Frontiers in Psychiatry 11: 717. 2 September 2020. doi:10.3389/fpsyt.2020.00717. PMID 32982805. 
  38. 38.0 38.1 "New generation antidepressants for depression in children and adolescents: a network meta-analysis". The Cochrane Database of Systematic Reviews 2021 (5): CD013674. May 2021. doi:10.1002/14651858.CD013674.pub2. PMID 34029378. 
  39. "Antidepressants and Quality of Life in Patients with Major Depressive Disorder - Systematic Review and Meta-analysis of Double-blind, Placebo-controlled RCTs". Acta Psychiatr Scand 147 (6): 545–560. March 2023. doi:10.1111/acps.13541. PMID 36905396. 
  40. "Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis". Transl Psychiatry 12 (1): 183. May 2022. doi:10.1038/s41398-022-01951-9. PMID 35508443. 
  41. "Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants". Int J Risk Saf Med 32 (2): 87–99. May 2021. doi:10.3233/JRS-200051. PMID 33044196. 
  42. 42.0 42.1 42.2 42.3 42.4 "Antidepressants for children and teenagers: what works for anxiety and depression?" (in en). NIHR Evidence (National Institute for Health and Care Research). 3 November 2022. doi:10.3310/nihrevidence_53342. https://evidence.nihr.ac.uk/collection/antidepressants-for-children-and-teenagers-what-works-anxiety-depression/. 
  43. 43.0 43.1 43.2 "Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review". World Psychiatry 20 (2): 244–275. June 2021. doi:10.1002/wps.20881. PMID 34002501. 
  44. 44.0 44.1 44.2 44.3 44.4 44.5 44.6 44.7 44.8 "Placebo Effect in the Treatment of Depression and Anxiety". Front Psychiatry 10: 407. 2019. doi:10.3389/fpsyt.2019.00407. PMID 31249537. 
  45. 45.0 45.1 45.2 45.3 45.4 "Meta-Analysis of Placebo Response in Adult Antidepressant Trials". CNS Drugs 33 (10): 971–980. October 2019. doi:10.1007/s40263-019-00662-y. PMID 31573058. 
  46. 46.0 46.1 National Collaborating Centre for Mental Health and the National Collaborating Centre for Primary Care (January 2011). "Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults". NICE clinical guideline 113. http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf. 
  47. "Optimal treatment of social phobia: systematic review and meta-analysis". Neuropsychiatric Disease and Treatment 8: 203–215. May 2012. doi:10.2147/NDT.S23317. PMID 22665997. 
  48. "Efficacy and tolerability of second-generation antidepressants in social anxiety disorder". International Clinical Psychopharmacology 23 (3): 170–179. May 2008. doi:10.1097/YIC.0b013e3282f4224a. PMID 18408531. 
  49. "Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)". The Cochrane Database of Systematic Reviews 2008 (1): CD001765. January 2008. doi:10.1002/14651858.CD001765.pub3. PMID 18253995. 
  50. "Evidence-based pharmacotherapy of obsessive-compulsive disorder". The International Journal of Neuropsychopharmacology 15 (8): 1173–1191. September 2012. doi:10.1017/S1461145711001829. PMID 22226028. 
  51. "Paroxetine prescribing information". https://www.apotex.com/us/en/products/downloads/pil/paxil_irtb_ins.pdf. 
  52. "Sertraline prescribing information". http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019839s070,020990s032lbl.pdf. 
  53. "Obsessive-compulsive disorder". Clinical Guideline 31. The National Institute for Health and Care Excellence. November 2005. http://www.nice.org.uk/nicemedia/pdf/cg031niceguideline.pdf. 
  54. "Drug treatment of obsessive-compulsive disorder". Dialogues in Clinical Neuroscience 12 (2): 187–197. June 2010. doi:10.31887/DCNS.2010.12.2/mkellner. PMID 20623923. 
  55. "Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis". J Affect Disord 218: 217–226. August 2017. doi:10.1016/j.jad.2017.04.068. PMID 28477500. 
  56. "Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents". P & T 37 (1): 32–38. January 2012. PMID 22346334. 
  57. "Antidepressants versus placebo for panic disorder in adults". The Cochrane Database of Systematic Reviews 2018 (4): CD010676. April 2018. doi:10.1002/14651858.CD010676.pub2. PMID 29620793. 
  58. "Antidepressants and benzodiazepines for panic disorder in adults". The Cochrane Database of Systematic Reviews 2016 (9): CD011567. September 2016. doi:10.1002/14651858.CD011567.pub2. PMID 27618521. 
  59. "Newer antidepressants and panic disorder: a meta-analysis". International Clinical Psychopharmacology 28 (1): 33–45. January 2013. doi:10.1097/YIC.0b013e32835a5d2e. PMID 23111544. 
  60. 60.0 60.1 60.2 "Eating disorders in over 8s: management". Clinical guideline [CG9]. United Kingdom: National Institute for Health Care Excellence (NICE). 28 January 2004. http://www.nice.org.uk/nicemedia/pdf/CG9FullGuideline.pdf. 
  61. "Bupropion: MedlinePlus Drug Information". https://www.nlm.nih.gov/medlineplus/druginfo/meds/a695033.html. 
  62. 62.0 62.1 "Practice guideline for the treatment of patients with eating disorders". National Guideline Clearinghouse. Agency for Healthcare Research and Quality. 5 July 2018. http://www.guidelines.gov/content.aspx?id=9318+. 
  63. "Evidence-based pharmacotherapy of eating disorders". Int. J. Neuropsychopharmacol. 15 (2): 189–207. March 2012. doi:10.1017/S1461145711000381. PMID 21414249. 
  64. "The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis". CNS Drugs 26 (4): 297–307. April 2012. doi:10.2165/11598970-000000000-00000. PMID 22452526. 
  65. "EULAR evidence-based recommendations for the management of fibromyalgia syndrome". Annals of the Rheumatic Diseases 67 (4): 536–541. April 2008. doi:10.1136/ard.2007.071522. PMID 17644548. 
  66. "Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia". The Cochrane Database of Systematic Reviews 1 (1): CD007115. January 2014. doi:10.1002/14651858.CD007115.pub3. PMID 24385423. 
  67. 67.0 67.1 "Amitriptyline for neuropathic pain in adults". The Cochrane Database of Systematic Reviews 2015 (7): CD008242. July 2015. doi:10.1002/14651858.CD008242.pub3. PMID 26146793. 
  68. "Antidepressants for the treatment of people with co-occurring depression and alcohol dependence". The Cochrane Database of Systematic Reviews 2018 (4): CD008581. April 2018. doi:10.1002/14651858.CD008581.pub2. PMID 29688573. 
  69. "Narcolepsy Information Page". 27 March 2019. https://www.ninds.nih.gov/Disorders/All-Disorders/Narcolepsy-Information-Page. 
  70. "Antidepressants for pain management in rheumatoid arthritis". The Cochrane Database of Systematic Reviews (11): CD008920. November 2011. doi:10.1002/14651858.CD008920.pub2. PMID 22071859. 
  71. "Antidepressants for depression in physically ill people". The Cochrane Database of Systematic Reviews (3): CD007503. March 2010. doi:10.1002/14651858.CD007503.pub2. PMID 20238354. 
  72. "Recent progress in pharmacological and non-pharmacological treatment options of major depression". Current Pharmaceutical Design 12 (4): 503–515. 2006. doi:10.2174/138161206775474422. PMID 16472142. 
  73. 73.0 73.1 "Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review". The Journal of Clinical Psychiatry 67 (12): 1836–1855. December 2006. doi:10.4088/JCP.v67n1203. PMID 17194261. http://pdfs.semanticscholar.org/02f0/a7fcfd218854147e6c3e52c3f213ab2d95e4.pdf. 
  74. "Prevalence and outcome of partial remission in depression". Journal of Psychiatry & Neuroscience 27 (4): 241–247. July 2002. PMID 12174733. 
  75. "Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments". The Journal of Clinical Psychiatry 59 (6): 279–288. June 1998. doi:10.4088/JCP.v59n0602. PMID 9671339. 
  76. "Antidepressant Use in Persons Aged 12 and Over: United States, 2005–2008". Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/data/databriefs/db76.htm. 
  77. "Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians". Canadian Journal of Psychiatry 45 (5): 476–481. June 2000. doi:10.1177/070674370004500509. PMID 10900529. 
  78. "Nobody can agree about antidepressants. Here's what you need to know". New Scientist (New Scientist Ltd). 2 October 2018. https://www.newscientist.com/article/mg23931980-100-nobody-can-agree-about-antidepressants-heres-what-you-need-to-know/. 
  79. 79.0 79.1 79.2 "The trouble with antidepressants: why the evidence overplays evidence and underplays risks—an essay by John B Warren". BMJ 370: m3200. 2020. doi:10.1136/bmj.m3200. PMID 32883743. 
  80. 80.0 80.1 80.2 "Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis". BMJ 378: e067606. August 2022. doi:10.1136/bmj-2021-067606. PMID 35918097. 
  81. 81.0 81.1 81.2 81.3 81.4 "Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That the Drugs Work: Effect Size and Method Bias Matter!". Front Psychiatry 9: 517. 2018. doi:10.3389/fpsyt.2018.00517. PMID 30386270. 
  82. "Effectiveness of antidepressants". BMJ 360: k1073. 2018. doi:10.1136/bmj.k1073. PMID 29523598. 
  83. 83.0 83.1 83.2 83.3 83.4 83.5 83.6 "Should antidepressants be used for major depressive disorder?". BMJ Evid Based Med 25 (4): 130. August 2020. doi:10.1136/bmjebm-2019-111238. PMID 31554608. 
  84. 84.0 84.1 "Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences". Contemp Clin Trials 43: 60–2. July 2015. doi:10.1016/j.cct.2015.05.005. PMID 25979317. 
  85. "Depression is both psychosocial and biological; antidepressants are both effective and in need of improvement; psychiatrists are both caring human beings and doctors who prescribe medications. Can we all agree on this? a commentary on 'Read & Moncrieff – depression: why drugs and electricity are not the answer'". Psychological Medicine 52 (8): 1411–1413. 2022. doi:10.1017/S0033291722000770. PMID 35362404. 
  86. 86.0 86.1 86.2 86.3 "Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials". PLOS ONE 15 (2): e0229381. 2020. doi:10.1371/journal.pone.0229381. PMID 32101579. Bibcode2020PLoSO..1529381H. 
  87. "New Directions in Research on Heterogeneity of Treatment Effects for Major Depression". JAMA Psychiatry 78 (5): 478–480. 2021. doi:10.1001/jamapsychiatry.2020.4489. PMID 33595616. 
  88. "Antidepressants versus placebo in major depression: an overview". World Psychiatry 14 (3): 294–300. 2015. doi:10.1002/wps.20241. PMID 26407778. 
  89. 89.0 89.1 89.2 "Why does the world have such a 'down' on antidepressants?". Journal of Psychopharmacology 22 (3): 223–226. 2008. doi:10.1177/0269881108091877. PMID 18541622. 
  90. "EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations". Epidemiology and Psychiatric Sciences 30: e35. 2021. doi:10.1017/S2045796021000147. PMID 33926608. 
  91. 91.0 91.1 91.2 91.3 91.4 "Depression: why drugs and electricity are not the answer". Psychological Medicine 52 (8): 1401–1410. 2022. doi:10.1017/S0033291721005031. PMID 35100527. https://repository.uel.ac.uk/download/0fd9663377e02e8033e12c27844d65b5e918406de4d7c7baca5031a8e8ba4c5a/408146/Read%20and%20Moncrieff%20Psych%20Med%20ROAR.pdf. 
  92. Unhappiness, sadness and 'depression'. London, UK: Palgrave Macmillan. 2017. pp. 108–110. ISBN 978-3-319-57657-2. 
  93. 93.0 93.1 93.2 93.3 93.4 93.5 "Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis". BMJ Open 9 (6): e024886. June 2019. doi:10.1136/bmjopen-2018-024886. PMID 31248914. 
  94. "Selective publication of antidepressant trials and its influence on apparent efficacy". New England Journal of Medicine 358 (3): 252–260. 2008. doi:10.1056/NEJMsa065779. PMID 18199864. 
  95. "Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials". PLOS Medicine 19 (1): e1003886. 2022. doi:10.1371/journal.pmed.1003886. PMID 35045113. 
  96. "Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study". BMJ Open 4 (7): e005535. 2014. doi:10.1136/bmjopen-2014-005535. PMID 25009136. 
  97. 97.0 97.1 97.2 97.3 Evidence-biased Antidepressant Prescription. Springer International Publishing. 2022. doi:10.1007/978-3-030-82587-4. ISBN 978-3-030-82586-7. 
  98. 98.0 98.1 98.2 "The Emperor's New Drugs: Medication and Placebo in the Treatment of Depression". Placebo. Handbook of Experimental Pharmacology. 225. Springer Berlin Heidelberg. 2014. pp. 291–303. doi:10.1007/978-3-662-44519-8_16. ISBN 978-3-662-44518-1. 
  99. "Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports". BMJ 352: i65. 2016. doi:10.1136/bmj.i65. PMID 26819231. 
  100. "Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers". Journal of the Royal Society of Medicine 109 (10): 381–392. 2016. doi:10.1177/0141076816666805. PMID 27729596. 
  101. "Rational use of antidepressant drugs". Psychotherapy and Psychosomatics 83 (4): 197–204. 2014. doi:10.1159/000362803. PMID 24969962. 
  102. 102.0 102.1 102.2 102.3 "Serotonin and depression: a disconnect between the advertisements and the scientific literature". PLOS Med 2 (12): e392. December 2005. doi:10.1371/journal.pmed.0020392. PMID 16268734. 
  103. 103.0 103.1 103.2 103.3 "Antidepressants and the Chemical Imbalance Theory of Depression: A Reflection and Update on the Discourse". The Behavior Therapist 38 (7): 206–213. October 2015. http://purl.flvc.org/fsu/fd/FSU_migr_csw_faculty_publications-0084. 
  104. 104.0 104.1 104.2 "Consumer Advertising of Psychiatric Medications Biases the Public Against Nonpharmacological Treatment". Ethical Human Psychology and Psychiatry 7 (3): 175–179. September 2005. doi:10.1891/1559-4343.7.3.175. ISSN 1559-4343. PMID 16604742. 
  105. 105.0 105.1 105.2 105.3 105.4 "Is the chemical imbalance an 'urban legend'? An exploration of the status of the serotonin theory of depression in the scientific literature". SSM – Mental Health 2: 100098. December 2022. doi:10.1016/j.ssmmh.2022.100098. ISSN 2666-5603. 
  106. "Major depressive disorder". Nature Reviews Disease Primers 2: 16065. 2016. doi:10.1038/nrdp.2016.65. PMID 27629598. https://kclpure.kcl.ac.uk/portal/en/publications/major-depressive-disorder(c382ec52-8506-4d39-9b77-cf86d64ad446).html. 
  107. "Management of depression in adults: summary of updated NICE guidance". BMJ 378: o1557. 2022. doi:10.1136/bmj.o1557. PMID 35858703. https://discovery.ucl.ac.uk/id/eprint/10152602/. 
  108. "No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy". Acta Psychiatrica Scandinavica 121 (3): 174–9. 2010. doi:10.1111/j.1600-0447.2009.01458.x. PMID 19703121. 
  109. "Update on augmentation of antidepressant response in resistant depression". Current Psychiatry Reports 7 (6): 435–40. 2005. doi:10.1007/s11920-005-0064-x. PMID 16318821. 
  110. "Combining Antidepressants for Treatment-Resistant Depression". The Journal of Clinical Psychiatry 63 (8): 685–93. 2002. doi:10.4088/JCP.v63n0805. PMID 12197448. 
  111. "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials". The Journal of Clinical Psychiatry 74 (11): 1101–7. 2013. doi:10.4088/JCP.13r08560. PMID 24330897. https://pdfs.semanticscholar.org/754c/e4bb94f6be37d53b562ffe90fcec9a17073b.pdf. 
  112. "Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review". The Lancet 361 (9358): 653–61. 2003. doi:10.1016/S0140-6736(03)12599-8. PMID 12606176. 
  113. "Identification and treatment of antidepressant tachyphylaxis". Innovations in Clinical Neuroscience 11 (3–4): 24–28. March 2014. PMID 24800130. 
  114. "The mechanisms of tolerance in antidepressant action". Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (7): 1593–1602. August 2011. doi:10.1016/j.pnpbp.2010.07.026. PMID 20728491. 
  115. "Treatment of recurrent depression". Expert Review of Neurotherapeutics 6 (11): 1735–1740. November 2006. doi:10.1586/14737175.6.11.1735. PMID 17144786. 
  116. "Enhancing the efficacy of antidepressants with psychotherapy". Journal of Psychopharmacology 20 (3 Suppl): 19–28. May 2006. doi:10.1177/1359786806064314. PMID 16644768. 
  117. "Voorkom Depressie - Preventieve Cognitieve Therapie". https://www.voorkomdepressie.nl/. 
  118. "Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis". JAMA Psychiatry 78 (8): 868–875. August 2021. doi:10.1001/jamapsychiatry.2021.0823. PMID 34009273. 
  119. "Coping With Side Effects of Depression Treatment". https://www.webmd.com/depression/features/coping-with-side-effects-of-depression-treatment. 
  120. "Serotonin syndrome: a brief review". CMAJ 168 (11): 1439–1442. May 2003. PMID 12771076. 
  121. "The serotonin syndrome". The New England Journal of Medicine 352 (11): 1112–1120. March 2005. doi:10.1056/NEJMra041867. PMID 15784664. http://toxicology.ucsd.edu/art%203%20serotonin%20syndrome.pdf. 
  122. "Serotonin syndrome. Presentation of 2 cases and review of the literature". Medicine 79 (4): 201–209. July 2000. doi:10.1097/00005792-200007000-00001. PMID 10941349. 
  123. "Serotonin syndrome: potentially fatal but difficult to recognize". The British Journal of General Practice 49 (448): 867–868. November 1999. PMID 10818648. 
  124. "The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis". PLOS ONE 12 (7): e0182088. 31 July 2017. doi:10.1371/journal.pone.0182088. PMID 28759599. Bibcode2017PLoSO..1282088S. "In our meta-analysis we found an association between exposure to ADs and new-onset diabetes, with a relative risk of 1.27. When we restricted the analysis to the studies to high NOS score the association between ADs and diabetes was even stronger. The results are in line with those from two previous meta-analyses that reported a 1.5-fold increase of diabetes among AD users.". 
  125. "Hypertensive crisis and cheese". Indian J Psychiatry 51 (1): 65–6. 2009. doi:10.4103/0019-5545.44910. PMID 19742203. 
  126. "Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression". Acta Psychiatrica Scandinavica. Supplementum 386: 22–27. 1995. doi:10.1111/j.1600-0447.1995.tb05920.x. PMID 7717091. 
  127. "Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence". Therapeutic Advances in Drug Safety 9 (6): 297–308. June 2018. doi:10.1177/2042098618772979. PMID 29854391. 
  128. "Causes and management of drug-induced long QT syndrome". Proceedings 23 (3): 250–255. July 2010. doi:10.1080/08998280.2010.11928628. PMID 20671821. 
  129. "Association between Antidepressants and Dementia Risk in Older Adults with Depression: A Systematic Review and Meta-Analysis". J Clin Med 12 (19): 6342. October 2023. doi:10.3390/jcm12196342. PMID 37834986. 
  130. Malm H (December 2012). "Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome". Ther Drug Monit 34 (6): 607–14. doi:10.1097/FTD.0b013e31826d07ea. PMID 23042258. 
  131. "Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials". Reproductive Toxicology 22 (4): 571–575. 2006. doi:10.1016/j.reprotox.2006.03.019. PMID 16720091. 
  132. 132.0 132.1 "Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis". DARU Journal of Pharmaceutical Sciences 20 (1): 75. 2012. doi:10.1186/2008-2231-20-75. PMID 23351929. 
  133. "A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight". General Hospital Psychiatry 36 (1): 13–8. 2014. doi:10.1016/j.genhosppsych.2013.08.002. PMID 24094568. 
  134. "Do findings differ across research design? The case of antidepressant use in pregnancy and malformations". J Popul Ther Clin Pharmacol 19 (2): e334–48. 2012. PMID 22946124. https://jptcp.com/index.php/jptcp/article/view/428. 
  135. "The fetal safety of fluoxetine: a systematic review and meta-analysis". J Obstet Gynaecol Can 35 (4): 362–9. April 2013. doi:10.1016/S1701-2163(15)30965-8. PMID 23660045. 
  136. "Selective serotonin reuptake inhibitors and malformations: case closed?". Semin Fetal Neonatal Med 18 (1): 19–22. February 2013. doi:10.1016/j.siny.2012.10.004. PMID 23228547. 
  137. "FDA Advising of Risk of Birth Defects with Paxil" (Press release). U.S. Food and Drug Administration. Archived from the original on 3 December 2013. Retrieved 29 November 2012.
  138. "Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis". JAMA Psychiatry 70 (4): 436–443. April 2013. doi:10.1001/jamapsychiatry.2013.684. PMID 23446732. 
  139. "Antidepressant Medication Use During Breastfeeding". Clinical Obstetrics and Gynecology 52 (3): 483–97. 2009. doi:10.1097/GRF.0b013e3181b52bd6. PMID 19661763. 
  140. "Antidepressants". Journal of Pharmacology and Pharmacotherapeutics 3 (3): 287–288. 2012. doi:10.1177/0976500X20120302. ProQuest 1033762996. http://www.jpharmacol.com/text.asp?2012%2F3%2F3%2F287%2F99452. Retrieved 21 March 2013. 
  141. "Antidepressant-induced mania: An overview of current controversies". Bipolar Disorders 5 (6): 407–20. 2003. doi:10.1046/j.1399-5618.2003.00067.x. PMID 14636364. 
  142. Benazzi F (1997). "Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice". J Affect Disord 46 (1): 73–7. doi:10.1016/S0165-0327(97)00082-7. PMID 9387089. 
  143. "A systematic review of manic/hypomanic and depressive switches in patients with bipolar disorder in naturalistic settings: The role of antidepressant and antipsychotic drugs". Eur Neuropsychopharmacol 73: 1–15. April 2023. doi:10.1016/j.euroneuro.2023.04.013. PMID 37119556. 
  144. 144.0 144.1 144.2 "Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration". BMJ 339: b2880. 2009. doi:10.1136/bmj.b2880. PMID 19671933. 
  145. "Expanding the black box – depression, antidepressants, and the risk of suicide". N. Engl. J. Med. 356 (23): 2343–6. 2007. doi:10.1056/NEJMp078015. PMID 17485726. 
  146. "Antidepressant Use in Children, Adolescents, and Adults". https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm096273. 
  147. "FDA Medication Guide for Antidepressants". https://www.fda.gov/downloads/Drugs/DrugSafety/ucm088660.pdf%E2%80%8E. 
  148. "Depression in adults: recognition and management". Clinical guideline [CG90]. The National Institute for Health and Care Excellence (NICE). 28 October 2009. http://www.nice.org.uk/nicemedia/pdf/CG90NICEguideline.pdf. 
  149. "Antidepressants and suicide: risk-benefit conundrums". Journal of Psychiatry and Neuroscience 28 (5): 331–337. 2003. PMID 14517576. 
  150. "Antidepressant drug use and the risk of suicide". International Review of Psychiatry 17 (3): 163–172. 2005. doi:10.1080/09540260500071624. PMID 16194787. http://www.davidhealy.org.php53-23.dfw1-1.websitetestlink.com/wp-content/uploads/2012/05/2005-Healy-Aldred-Antidepressants-and-Suicide1.pdf. 
  151. The Oxford handbook of impulse control disorders. Oxford: Oxford University Press. 2012. ISBN 978-0-19-538971-5. 
  152. "Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors". The Journal of Sexual Medicine 5 (1): 227–233. January 2008. doi:10.1111/j.1743-6109.2007.00630.x. PMID 18173768. 
  153. "Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases". The International Journal of Risk & Safety in Medicine 29 (3–4): 125–134. 4 June 2018. doi:10.3233/JRS-180744. PMID 29733030. 
  154. "Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". The Journal of Clinical Psychiatry 62 (Suppl 3): 10–21. 2001. PMID 11229449. 
  155. "Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis". Journal of Clinical Psychopharmacology 29 (3): 259–266. June 2009. doi:10.1097/JCP.0b013e3181a5233f. PMID 19440080. 
  156. "[Antidepressants and sexual stimulation: the correlation]" (in fr). L'Encephale 24 (3): 180–184. 1998. PMID 9696909. 
  157. "Biological Perspectives". Perspectives in Psychiatric Care 38 (3): 111–6. 2009. doi:10.1111/j.1744-6163.2002.tb00665.x. PMID 12385082. 
  158. "Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors". Hum Psychopharmacol 23 (4): 321–6. 2008. doi:10.1002/hup.929. PMID 18278806. 
  159. "Other Antidepressants". Antidepressants. Handbook of Experimental Pharmacology. 250. 8 September 2018. pp. 325–355. doi:10.1007/164_2018_167. ISBN 978-3-030-10948-6. 
  160. "Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs". Clin Neuropsychiatry 16 (2): 75–85. April 2019. PMID 34908941. 
  161. 161.0 161.1 161.2 161.3 "Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research". Front Psychiatry 12: 792960. 2021. doi:10.3389/fpsyt.2021.792960. PMID 34970173. 
  162. "SSRI-induced apathy syndrome: a clinical review". J Psychiatr Pract 10 (3): 196–9. May 2004. doi:10.1097/00131746-200405000-00010. PMID 15330228. 
  163. "SSRI-Induced Indifference". Psychiatry (Edgmont) 7 (10): 14–8. October 2010. PMID 21103140. 
  164. "Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study". Br J Psychiatry 195 (3): 211–7. September 2009. doi:10.1192/bjp.bp.108.051110. PMID 19721109. 
  165. "Emotional blunting with antidepressant treatments: A survey among depressed patients". J Affect Disord 221: 31–35. October 2017. doi:10.1016/j.jad.2017.05.048. PMID 28628765. https://ora.ox.ac.uk/objects/uuid:8a7067a3-7b21-481f-ac80-32f1929d3ff7. 
  166. "Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects". Curr Drug Saf 13 (3): 176–186. 2018. doi:10.2174/1574886313666180605095130. PMID 29866014. http://roar.uel.ac.uk/7564/1/7564.pdf. 
  167. 167.0 167.1 "Are all antidepressants the same? The consumer has a point". Psychol Med 53 (9): 4004–4011. March 2022. doi:10.1017/S0033291722000678. PMID 35346413. 
  168. "Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents". J Child Adolesc Psychopharmacol 11 (2): 181–6. 2001. doi:10.1089/104454601750284090. PMID 11436958. 
  169. "Antidepressants: misnamed and misrepresented". World Psychiatry 14 (3): 302–3. October 2015. doi:10.1002/wps.20243. PMID 26407780. 
  170. "Efficacy of Aomelatine and Escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial". Int J Neuropsychopharmacol 16 (10): 2219–34. November 2013. doi:10.1017/S1461145713000679. PMID 23823799. 
  171. "Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment". J Affect Disord 283: 472–479. March 2021. doi:10.1016/j.jad.2020.11.106. PMID 33516560. 
  172. "Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects". Pharmacotherapy 17 (1): 10–21. 1997. doi:10.1002/j.1875-9114.1997.tb03674.x. PMID 9017762. https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1997.tb03674.x. Retrieved 17 January 2020. 
  173. "mirtazapine (Rx) – Remeron, Remeron SolTab". WebMD. http://reference.medscape.com/drug/remeron-soltab-mirtazapine-342966. 
  174. Papakostas GI (2008). "Tolerability of modern antidepressants". J Clin Psychiatry 69 (Suppl E1): 8–13. PMID 18494538. 
  175. "Meta-analysis: pharmacologic treatment of obesity". Ann. Intern. Med. 142 (7): 532–46. April 2005. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465. 
  176. "Effexor Medicines Data Sheet". Wyeth Pharmaceuticals Inc. 2006. http://www.wyeth.com/content/showlabeling.asp?id=99. 
  177. Kang, Sunyoung; Han, Minkyung; Park, Chun Il; Jung, Inkyung; Kim, Eun Hwa; Boo, Young Jun; Kang, Jee In; Kim, Se Joo (2021-06-29). "Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study" (in en). Scientific Reports 11 (1): 13461. doi:10.1038/s41598-021-92821-9. ISSN 2045-2322. PMID 34188108. Bibcode2021NatSR..1113461K. 
  178. Rizzoli, R.; Cooper, C.; Reginster, J.-Y.; Abrahamsen, B.; Adachi, J. D.; Brandi, M. L.; Bruyère, O.; Compston, J. et al. (September 2012). "Antidepressant medications and osteoporosis". Bone 51 (3): 606–613. doi:10.1016/j.bone.2012.05.018. ISSN 1873-2763. PMID 22659406. https://pubmed.ncbi.nlm.nih.gov/22659406/. 
  179. Zhou, C.; Fang, L.; Chen, Y.; Zhong, J.; Wang, H.; Xie, P. (June 2018). "Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis". Osteoporosis International 29 (6): 1243–1251. doi:10.1007/s00198-018-4413-0. ISSN 1433-2965. PMID 29435621. https://pubmed.ncbi.nlm.nih.gov/29435621/. 
  180. 180.0 180.1 "The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis". Psychother Psychosom 86 (5): 268–282. 2017. doi:10.1159/000477940. PMID 28903117. 
  181. 181.00 181.01 181.02 181.03 181.04 181.05 181.06 181.07 181.08 181.09 181.10 181.11 "Antidepressant discontinuation syndrome". American Family Physician 74 (3): 449–456. August 2006. PMID 16913164. 
  182. 182.0 182.1 182.2 182.3 182.4 182.5 "A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?". Addictive Behaviors 97: 111–121. October 2019. doi:10.1016/j.addbeh.2018.08.027. PMID 30292574. 
  183. 183.0 183.1 "Neuropharmacological classification of antidepressant agents based on their mechanisms of action". Archives of Medicine and Health Sciences 6 (1): 81. 2018. doi:10.4103/amhs.amhs_7_18. ISSN 2321-4848. 
  184. 184.0 184.1 "Antidepressants-A Misnomer? Clinical Impressionism or Scientific Empiricism?". Prim Care Companion CNS Disord 24 (3). June 2022. doi:10.4088/PCC.21br03084. PMID 35714379. 
  185. 185.0 185.1 185.2 Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. 19 November 2020. ISBN 978-1-108-92602-7. https://books.google.com/books?id=eyFGEAAAQBAJ. 
  186. "Antidepressants". Psychiatry. John Wiley & Sons, Ltd. 8 August 2008. pp. 2123–2160. doi:10.1002/9780470515167.ch101. ISBN 9780470515167. 
  187. 187.0 187.1 187.2 187.3 Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. 2011. ISBN 978-0-07-162442-8. [needs update]
  188. 188.0 188.1 188.2 188.3 188.4 188.5 188.6 "The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis". J Hist Neurosci 12 (2): 207–20. June 2003. doi:10.1076/jhin.12.2.207.15535. PMID 12953623. 
  189. 189.0 189.1 189.2 "The serotonin theory of depression: a systematic umbrella review of the evidence". Mol Psychiatry 28 (8): 3243–3256. July 2022. doi:10.1038/s41380-022-01661-0. PMID 35854107. 
  190. 190.0 190.1 "The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression". Metabolic Brain Disease 24 (1): 27–53. March 2009. doi:10.1007/s11011-008-9118-1. PMID 19085093. 
  191. 191.0 191.1 "Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders". Neuropharmacology 62 (1): 63–77. January 2012. doi:10.1016/j.neuropharm.2011.07.036. PMID 21827775. 
  192. "Epigenetics, depression and antidepressant treatment". Current Pharmaceutical Design 18 (36): 5879–5889. 2012. doi:10.2174/138161212803523590. PMID 22681167. 
  193. "Epigenetic mechanisms of depression and antidepressant action". Annual Review of Pharmacology and Toxicology 53 (1): 59–87. January 2013. doi:10.1146/annurev-pharmtox-010611-134540. PMID 23020296. 
  194. "Expert reaction to a review paper on the 'Serotonin Theory of Depression'". https://www.sciencemediacentre.org/expert-reaction-to-a-review-paper-on-the-serotonin-theory-of-depression/. 
  195. 195.0 195.1 "Response to Criticism of Our Serotonin Paper". 28 July 2022. https://www.madinamerica.com/2022/07/response-criticism-serotonin-paper/. 
  196. 196.0 196.1 196.2 "The effects of reserpine on depression: A systematic review". J Psychopharmacol 37 (3): 248–260. August 2022. doi:10.1177/02698811221115762. PMID 36000248. 
  197. "The Media and the Chemical Imbalance Theory of Depression". Society 45 (1): 35–45. 28 November 2007. doi:10.1007/s12115-007-9047-3. ISSN 0147-2011. 
  198. The Emperor's New Drugs: Exploding the Antidepressant Myth. Basic Books. 26 January 2010. ISBN 978-0-465-02104-8. OCLC 1037471689. https://books.google.com/books?id=wk-OxcTKyi4C. 
  199. "Depression: why drugs and electricity are not the answer". Psychol Med 52 (8): 1401–1410. June 2022. doi:10.1017/S0033291721005031. PMID 35100527. https://repository.uel.ac.uk/download/0fd9663377e02e8033e12c27844d65b5e918406de4d7c7baca5031a8e8ba4c5a/408146/Read%20and%20Moncrieff%20Psych%20Med%20ROAR.pdf. 
  200. "False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs". Ethical Human Psychology and Psychiatry 20 (1): 6–16. July 2018. doi:10.1891/1559-4343.20.1.6. ISSN 1559-4343. 
  201. 201.0 201.1 201.2 "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet 391 (10128): 1357–1366. April 2018. doi:10.1016/S0140-6736(17)32802-7. PMID 29477251. 
  202. "Irving Kirsch opens a window on antidepressant medications". Am J Clin Hypn 65 (3): 223–240. January 2023. doi:10.1080/00029157.2022.2121678. PMID 36638223. 
  203. "Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression". BMJ Evid Based Med 27 (2): 69–73. April 2022. doi:10.1136/bmjebm-2020-111600. PMID 33593736. 
  204. "Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review". Int J Neuropsychopharmacol 25 (6): 433–447. June 2022. doi:10.1093/ijnp/pyac009. PMID 35078210. 
  205. "The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance". Eur J Appl Physiol 122 (11): 2321–2329. August 2022. doi:10.1007/s00421-022-05029-8. PMID 36006479. https://nrl.northumbria.ac.uk/id/eprint/49965/1/Brietzke%20et%20al.%202022%20The%20reward%20of%20placebo_R1.pdf. 
  206. "Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries". Med Sci Monit 11 (5): MS54–65. May 2005. PMID 15874901. 
  207. 207.0 207.1 207.2 207.3 "Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission". BMJ Evid Based Med 25 (2): 46–48. April 2020. doi:10.1136/bmjebm-2019-111161. PMID 30975717. 
  208. "A systematic review of comparative efficacy of treatments and controls for depression". PLOS ONE 7 (7): e41778. 2012. doi:10.1371/journal.pone.0041778. PMID 22860015. Bibcode2012PLoSO...741778K. 
  209. Kirsch, I.; Sapirstein, G (26 June 1998). "Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication". Prevention and Treatment 1 (2): Article 0002a. doi:10.1037/1522-3736.1.1.12a. http://journals.apa.org/prevention/volume1/pre0010002a.html. 
  210. "Antidepressants and the placebo response". Epidemiol Psychiatr Soc 18 (4): 318–22. 2009. doi:10.1017/s1121189x00000282. PMID 20170046. 
  211. "Selective Serotonin Reuptake Inhibitors". Antidepressants: Past, Present and Future. Berlin: Springer. 2004. pp. 241–62. ISBN 978-3-540-43054-4. https://books.google.com/books?id=sO_hArhCxwMC&pg=PA241. 
  212. "Antidepressant drug effects and depression severity: a patient-level meta-analysis". JAMA 303 (1): 47–53. January 2010. doi:10.1001/jama.2009.1943. PMID 20051569. 
  213. "In Defense of Antidepressants". The New York Times. 7 September 2011. https://www.nytimes.com/2011/07/10/opinion/sunday/10antidepressants.html. 
  214. "Antidepressants work, sort of—our system of care does not". Journal of Clinical Psychopharmacology 30 (2): 101–104. April 2010. doi:10.1097/JCP.0b013e3181d52dea. PMID 20520282. https://zenodo.org/record/890741. 
  215. "Antidepressants: Conundrums and Complexities of Efficacy Studies". Journal of Clinical Psychopharmacology 36 (1): 1–4. February 2016. doi:10.1097/jcp.0000000000000455. PMID 26658086. https://zenodo.org/record/890747. 
  216. "Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression". Bioorganic & Medicinal Chemistry 17 (19): 6890–6897. October 2009. doi:10.1016/j.bmc.2009.08.025. PMID 19740668. 
  217. Goldenberg MM (November 2013). "Pharmaceutical approval update". P T 38 (11): 705–7. PMID 24391391. 
  218. American Pharmacists Association (2013). "Vortioxetine: Atypical antidepressant". http://www.pharmacist.com/vortioxetine-atypical-antidepressant. 
  219. Los Angeles Times (2013). "FDA approves a new antidepressant: Brintellix". https://www.latimes.com/science/sciencenow/la-sci-fda-approval-antidepressant-20130930-story.html. 
  220. "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology 510 (1–2): 49–57. March 2005. doi:10.1016/j.ejphar.2005.01.018. PMID 15740724. 
  221. Stahl's essential psychopharmacology : neuroscientific basis and practical application. with illustrations by Muntner N (4th ed.). Cambridge: Cambridge University Press. 2013. ISBN 978-1107686465. 
  222. 222.0 222.1 "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur J Pharmacol 340 (2–3): 249–258. 1997. doi:10.1016/S0014-2999(97)01393-9. PMID 9537821. 
  223. Gillman PK (July 2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated". British Journal of Pharmacology 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMID 17471183. 
  224. "Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis". CMAJ 159 (10): 1245–1252. November 1998. PMID 9861221. 
  225. Cristancho, Mario (20 November 2012). "Atypical Depression in the 21st Century: Diagnostic and Treatment Issues". Psychiatric Times 28 (1). http://www.psychiatrictimes.com/major-depressive-disorder/atypical-depression-21st-century-diagnostic-and-treatment-issues. Retrieved 23 November 2013. 
  226. "Current place of monoamine oxidase inhibitors in the treatment of depression". CNS Drugs 27 (10): 789–797. October 2013. doi:10.1007/s40263-013-0097-3. PMID 23934742. 
  227. "Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks". The Journal of Clinical Psychiatry 48 (2): 55–59. February 1987. PMID 3542985. 
  228. "Phenelzine vs atenolol in social phobia. A placebo-controlled comparison". Archives of General Psychiatry 49 (4): 290–300. April 1992. doi:10.1001/archpsyc.49.4.290. PMID 1558463. 
  229. "Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine". The British Journal of Psychiatry 161 (3): 353–360. September 1992. doi:10.1192/bjp.161.3.353. PMID 1393304. 
  230. "Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome". Archives of General Psychiatry 55 (12): 1133–1141. December 1998. doi:10.1001/archpsyc.55.12.1133. PMID 9862558. 
  231. "Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial". Archives of General Psychiatry 56 (5): 431–437. May 1999. doi:10.1001/archpsyc.56.5.431. PMID 10232298. 
  232. "Phenelzine v imipramine in atypical depression. A preliminary report". Archives of General Psychiatry 41 (7): 669–677. July 1984. doi:10.1001/archpsyc.1984.01790180039005. PMID 6375621. 
  233. "Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study". Archives of General Psychiatry 41 (11): 1105–1109. November 1984. doi:10.1001/archpsyc.1983.01790220095015. PMID 6388524. 
  234. "A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives". The International Journal of Eating Disorders 15 (1): 1–9. January 1994. doi:10.1002/1098-108X(199401)15:1<1::AID-EAT2260150102>3.0.CO;2-E. PMID 8124322. 
  235. "A double-blind trial of phenelzine in bulimia". Journal of Psychiatric Research 19 (2–3): 485–489. 1985. doi:10.1016/0022-3956(85)90058-5. PMID 3900362. 
  236. "Phenelzine vs placebo in 50 patients with bulimia". Archives of General Psychiatry 45 (5): 471–475. May 1988. doi:10.1001/archpsyc.1988.01800290091011. PMID 3282482. 
  237. "A pilot study of phenelzine in the treatment of post-traumatic stress disorder". The British Journal of Psychiatry 150 (2): 252–255. February 1987. doi:10.1192/bjp.150.2.252. PMID 3651684. 
  238. "Efficacy of phenelzine and haloperidol in borderline personality disorder". Archives of General Psychiatry 50 (5): 377–385. May 1993. doi:10.1001/archpsyc.1993.01820170055007. PMID 8489326. 
  239. "Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?". Psychopharmacology Bulletin 42 (2): 64–74. 2009. PMID 19629023. 
  240. "Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders". Acta Psychiatrica Scandinavica. Supplementum 360: 29–34. 1990. doi:10.1111/j.1600-0447.1990.tb05321.x. PMID 2248064. 
  241. 241.0 241.1 "SPRAVATO™ (Esketamine) nasal spray FDA label". Food and Drug Administration. 5 March 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf. 
  242. "Dextromethorphan/Bupropion: First Approval". CNS Drugs 36 (11): 1229–1238. November 2022. doi:10.1007/s40263-022-00968-4. PMID 36301443. https://figshare.com/articles/online_resource/Dextromethorphan_Bupropion_First_Approval/21320970. 
  243. "Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence". Expert Review of Neurotherapeutics 23 (3): 205–212. March 2023. doi:10.1080/14737175.2023.2192402. PMID 36943010. 
  244. "Depressive Disorders". http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html?qt=depression&alt=sh#v1028590. 
  245. The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. 2012. ISBN 978-0-470-97969-3. 
  246. "Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents". The Cochrane Database of Systematic Reviews 2014 (11): CD008324. November 2014. doi:10.1002/14651858.CD008324.pub3. PMID 25433518. PMC 8556660. http://vuir.vu.edu.au/33744/1/Cox%20et%20al%202012%20Psychological%20therapies%20versus%20antidepressant%20medication%20%28Review%29.pdf. 
  247. "Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies". Journal of Clinical Psychopharmacology 19 (5): 427–34. 1999. doi:10.1097/00004714-199910000-00006. PMID 10505584. 
  248. "Lithium treatment reduces suicide risk in recurrent major depressive disorder". J Clin Psychiatry 68 (3): 380–83. March 2007. doi:10.4088/JCP.v68n0304. PMID 17388706. 
  249. "A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report". American Journal of Psychiatry 163 (9): 1519–30. 2006. doi:10.1176/appi.ajp.163.9.1519. PMID 16946176. 
  250. The Prescriber's Guide (Stahl's Essential Psychopharmacology). Cambridge University Press. 2011. p. 39. 
  251. "Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review". Southern Medical Journal 85 (10): 985–991. October 1992. doi:10.1097/00007611-199210000-00012. PMID 1411740. 
  252. 252.0 252.1 "Psychostimulants in the treatment of depression : a review of the evidence". CNS Drugs 21 (3): 239–257. 2007. doi:10.2165/00023210-200721030-00004. PMID 17338594. 
  253. 253.0 253.1 "Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders". International Clinical Psychopharmacology 3 (3): 255–66. 1988. doi:10.1097/00004850-198807000-00007. PMID 3153713. 
  254. "Amphetamine, past and present – a pharmacological and clinical perspective". J. Psychopharmacol. 27 (6): 479–96. June 2013. doi:10.1177/0269881113482532. PMID 23539642. 
  255. Czygan FC (2003). "Kulturgeschichte und Mystik des Johanniskrauts: Vom 2500 Jahre alten Apotropaikum zum aktuellen Antidepressivum" (in de). Pharmazie in unserer Zeit 32 (3): 184–90. doi:10.1002/pauz.200390062. PMID 12784538. 
  256. "St John's wort for depression—an overview and meta-analysis of randomized clinical trials". BMJ 313 (7052): 253–258. August 1996. doi:10.1136/bmj.313.7052.253. PMID 8704532. 
  257. "Herbal supplement use and blood lead levels of United States adults". Journal of General Internal Medicine 24 (11): 1175–1182. November 2009. doi:10.1007/s11606-009-1050-5. PMID 19575271. 
  258. "Current St John's wort research from mode of action to clinical efficacy". Pharmacological Research 47 (2): 101–109. February 2003. doi:10.1016/S1043-6618(02)00266-9. PMID 12543057. 
  259. "Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology". Journal of Psychopharmacology 15 (1): 47–54. March 2001. doi:10.1177/026988110101500109. PMID 11277608. 
  260. "Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic Acid". Chest 21 (4): 385–438. 1952. doi:10.1378/chest.21.4.385. PMID 14906149. 
  261. "The Antidepressant Drama". The treatment of depression: bridging the 21st century. American Psychiatric Pub. 2001. pp. 10–11. ISBN 978-0-88048-397-1. https://books.google.com/books?id=LAmBVolIG5kC. 
  262. The psychopharmacologists: interviews. London: Chapman and Hall. 1996. p. 8. ISBN 978-1-86036-008-4. 
  263. The Psychopharmacologists. 2. A Hodder Arnold Publication. 1998. pp. 132–4. ISBN 978-1-86036-010-7. 
  264. "Isoniazid and Its Isopropyl Derivative in the Therapy of Tuberculosis in Humans: Comparative Therapeutic and Toxicologic Properties". Chest 23 (1): 1–15. 1953. doi:10.1378/chest.23.1.1. PMID 12998444. 
  265. 265.0 265.1 265.2 265.3 "Half a Century of Antidepressant Drugs". Journal of Clinical Psychopharmacology 27 (6): 555–9. 2007. doi:10.1097/jcp.0b013e3181bb617. PMID 18004120. 
  266. "Psychic Energizer". Time. 15 April 1957. http://www.time.com/time/magazine/article/0,9171,862555,00.html. 
  267. Kuhn R (1958). "The treatment of depressive states with G 22355 (Imipramine Hydrochloride)". The American Journal of Psychiatry 115 (5): 459–64. doi:10.1176/ajp.115.5.459. PMID 13583250. 
  268. "Tranquilizers". cmcsb.com. http://www.cmcsb.com/tranquil.htm. 
  269. 269.0 269.1 Healy D (1999). "The Three Faces of the Antidepressants: A Critical Commentary on the Clinical-Economic Context of Diagnosis". The Journal of Nervous & Mental Disease 187 (3): 174–80. doi:10.1097/00005053-199903000-00007. PMID 10086474. 
  270. Pletscher A (1991). "The discovery of antidepressants: A winding path". Experientia 47 (1): 4–8. doi:10.1007/BF02041242. PMID 1999242. 
  271. Domino EF (1999). "History of modern psychopharmacology: A personal view with an emphasis on antidepressants". Psychosomatic Medicine 61 (5): 591–8. doi:10.1097/00006842-199909000-00002. PMID 10511010. http://www.psychosomaticmedicine.org/cgi/pmidlookup?view=long&pmid=10511010. 
  272. "A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine". The Journal of Pharmacology and Experimental Therapeutics 193 (3): 804–11. 1975. PMID 1151730. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=1151730. Retrieved 24 April 2009. 
  273. "Tolerability and safety of novel antidepressants". European Psychiatry 11: 206s. 1996. doi:10.1016/0924-9338(96)88597-X. 
  274. "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial". Psychological Medicine 49 (4): 655–663. March 2019. doi:10.1017/S0033291718001356. PMID 29903051. 
  275. (in en) Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression - Full Text View - ClinicalTrials.gov. 15 February 2017. https://clinicaltrials.gov/ct2/show/NCT02914769. 
  276. "FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder" (in en). 22 November 2019. https://www.businesswire.com/news/home/20191122005452/en/FDA-grants-Breakthrough-Therapy-Designation-to-Usona-Institutes-psilocybin-program-for-major-depressive-disorder. 
  277. "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis" (in English). The Lancet. Psychiatry 7 (7): 581–601. July 2020. doi:10.1016/S2215-0366(20)30137-1. PMID 32563306. 
  278. "Antidepressant Use Rises as Recession Feeds Wave of Worry". The Guardian (London). 11 June 2010. https://www.theguardian.com/society/2010/jun/11/antidepressant-prescriptions-rise-nhs-recession. 
  279. "Focus on: Antidepressant prescribing". QualityWatch (Nuffield Trust/Health Foundation). http://www.qualitywatch.org.uk/focus-on/antidepressant-prescribing. 
  280. "Teenagers' use of antidepressants is rising with variations across regions and ethnic groups" (in en). NIHR Evidence (National Institute for Health and Care Research). 18 November 2020. doi:10.3310/alert_42239. https://evidence.nihr.ac.uk/alert/teenagers-use-of-antidepressants-is-rising-with-variations-across-regions-and-ethnic-groups/. 
  281. "Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998–2017: A population-based cohort study". PLOS Medicine 17 (7): e1003215. July 2020. doi:10.1371/journal.pmed.1003215. PMID 32697803. 
  282. "Peaks in number of young people prescribed antidepressants coincide with lockdowns" (in en-US). 23 June 2021. https://pharmaceutical-journal.com/article/news/peaks-in-number-of-young-people-prescribed-antidepressants-coincide-with-lockdowns. 
  283. "Secondary care specialist visits made by children and young people prescribed antidepressants in primary care: a descriptive study using the QResearch database". BMC Medicine 18 (1): 93. April 2020. doi:10.1186/s12916-020-01560-7. PMID 32349753. 
  284. "GPs giving antidepressants to children against guidelines" (in en). 4 November 2022. https://www.theguardian.com/society/2022/nov/04/gps-giving-antidepressants-to-children-against-guidelines. 
  285. "High-quality antidepressant prescribing: please consider whether "perfection is the enemy of progress"". BMC Medicine 18 (1): 150. May 2020. doi:10.1186/s12916-020-01621-x. PMID 32438910. 
  286. 286.0 286.1 "Waking up from sadness: Many find trouble getting off antidepressants". http://america.aljazeera.com/articles/2014/1/22/patients-mostly-womenfindtroublegettingoffofantidepressants.html. 
  287. "By the numbers: Antidepressant use on the rise". https://www.apa.org/monitor/2017/11/numbers.aspx. 
  288. "Top 200 generic drugs by units in 2010". http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf. "Top 200 brand drugs by units in 2010". http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727256/article.pdf. 
  289. "GIPdatabank". Gipdatabank.nl. http://www.gipdatabank.nl/index.asp?scherm=tabellenFrameSet&infoType=g&tabel=01-basis&item=N06AB. 
  290. "Adherence to Long Term Therapies: Evidence for Action". 2003. https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1. 
  291. "Aspects of patient and clinician language predict adherence to antidepressant medication". Journal of the American Board of Family Medicine 26 (4): 409–420. July 2013. doi:10.3122/jabfm.2013.04.120201. PMID 23833156. 
  292. "Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review". Journal of Affective Disorders 193: 1–10. March 2016. doi:10.1016/j.jad.2015.12.029. PMID 26748881. 
  293. 293.0 293.1 293.2 Ecks S (2005). "Pharmaceutical Citizenship: Antidepressant Marketing and the Promise of Demarginalization in India". Anthropology & Medicine 12 (3): 239–254. doi:10.1080/13648470500291360. PMID 26873669. 
  294. 294.0 294.1 ""Local Biologies and Human Difference". An anthropology of biomedicine (1st ed.). Chichester, West Sussex: Wiley-Blackwell. 2010. pp. 83–109. ISBN 978-1-4051-1071-6. https://archive.org/details/anthropologybiom00lock. 
  295. "LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake". Science 317 (5843): 1390–3. 2007. doi:10.1126/science.1147614. PMID 17690258. Bibcode2007Sci...317.1390Z. 
  296. Fong PP (2001). "Antidepressants in Aquatic Organisms: A Wide Range of Effects". Pharmaceuticals and personal care products in the environment: scientific and regulatory issues. Washington, DC: American Chemical Society. pp. 264–281. ISBN 978-0-8412-3739-1. 
  297. "Determination of select antidepressants in fish from an effluent-dominated stream". Environ. Toxicol. Chem. 24 (2): 464–9. 2005. doi:10.1897/04-081r.1. PMID 15720009. 
  298. "Ecotoxicology of human pharmaceuticals". Aquat. Toxicol. 76 (2): 122–59. 2006. doi:10.1016/j.aquatox.2005.09.009. PMID 16257063. Bibcode2006AqTox..76..122F. 
  299. "Feeding rank and brain serotonergic activity in rainbow trout Onchorhynchus my kiss". J. Exp. Biol. 179: 197–211. 1993. doi:10.1242/jeb.179.1.197. 
  300. "Serotonin and aggressive motivation in crustaceans: altering the decision to retreat". Proc. Natl. Acad. Sci. U.S.A. 94 (11): 5939–42. 1997. doi:10.1073/pnas.94.11.5939. PMID 9159179. Bibcode1997PNAS...94.5939H. 
  301. "Fluoxetine treatment decreases territorial aggression in a coral reef fish". Physiol. Behav. 79 (4–5): 719–24. 2003. doi:10.1016/S0031-9384(03)00211-7. PMID 12954414. 
  302. "Effects of perinatal exposure to waterborne Fluoxetine on memory processing in the cuttlefish Sepia officinalis". Aquat. Toxicol. 132–133: 84–91. 2013. doi:10.1016/j.aquatox.2013.02.004. PMID 23474317. Bibcode2013AqTox.132...84D. 
  303. "Pharmacokinetics of selective serotonin reuptake inhibitors". Pharmacology & Therapeutics 85 (1): 11–28. January 2000. doi:10.1016/s0163-7258(99)00048-0. PMID 10674711. http://www.science.smith.edu/departments/Biochem/Chm_357/Articles/SSRIs.pdf. 
  304. "Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug Fluoxetine". Archives of Environmental Contamination and Toxicology 52 (2): 163–170. February 2007. doi:10.1007/s00244-005-7190-7. PMID 17160491. Bibcode2007ArECT..52..163N. 

Further reading

External links